Clinical trial NCT04307940
Conditions: Pain
Keywords: Postsurgical Dental Pain
Sponsor: Bayer
Start date: 2020-03-12; Completion date: 2020-10-05
Enrollment: 221 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
With this study researchers want to collect information on how long the pain relief lasts after a fixed dose of naproxen sodium or hydrocodone/acetaminophen or placebo (contains no medication) over 12 hours in subjects experiencing moderate to severe pain after having their wisdom teeth removed. Naproxen Sodium (Aleve®) is a drug that is used for the temporary relief of minor aches and pains.

Hydrocodone/Acetaminophen is a combination drug used to relieve moderate to severe pain. It contains an opioid (narcotic) pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen).

Detailed description:

Arms: arm 1: After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1) arm 2: After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1) arm 3: After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1)
Interventions: intervention 1: Naproxen Sodium (Aleve, BAY117031) intervention 2: Hydrocodone/Acetaminophen intervention 3: Placebo
Intervention descriptions: intervention 1: 220 mg per tablet, two tablets (440 mg), intake a single dose orally. intervention 2: 5/325 mg per tablet, two tablets (10/650 mg), intake a single dose orally. intervention 3: two tablets, intake a single dose orally.

Protocol documents:
Prot_000.pdf: 
 
Document Type: 
Clinical Study Protocol 
Official Title: 
A Randomized, Double-Blind, Placebo-Controlled Trial to Compare 
the Analgesic Efficacy and Safety of Naproxen Sodium Tablets and 
Hydrocodone/Acetaminophen Tablets in Postsurgical Dental Pain 
NCT Number: 
NCT04307940 
Document Date: 
19 NOV 2019 
 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 1 of 54 
 
 
Title Page 
Protocol Title: A Randomized, Double-Blind, Placebo-Controlled Trial to Compare the 
Analgesic Efficacy and Safety of Naproxen Sodium Tablets and 
Hydrocodone/Acetaminophen Tablets in Postsurgical Dental Pain 
Protocol Number: 20536 
Amendment Number: Not applicable 
Compound Number: BAY 117031 / Naproxen Sodium 
Study Phase: Phase 4 
 
 
Sponsor Name: Bayer HealthCare LLC, Consumer Health 
Legal Registered Address: 100 Bayer Boulevard 
 
Whippany, NJ 07981-0915, USA 
 
Regulatory Agency Identifier Number(s): Not applicable  
 
Approval Date: 19-Nov-2019  
 
 
 
 
Confidential 
The information provided in this document is strictly confidential and is intended solely for the performance of 
the clinical investigation.  Reproduction or disclosure of this document, whether in part or in full, to parties not 
associated with the clinical investigation or its use for any other purpose without the prior written consent of the 
sponsor is not permitted. 
Throughout this document, symbols indicating proprietary names (®, TM) may not be displayed. Hence, the 
appearance of product names without these symbols does not imply that these names are not protected. 
 


PPD


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 3 of 54 
 
Table of Contents 
Title Page ............................................................................................................................... 1 
Sponsor Signatory ................................................................................................................ 2 
Table of Contents ................................................................................................................. 3 
Table of Tables ..................................................................................................................... 5 
1. 
Protocol Summary ........................................................................................................ 6 
1.1 
Synopsis ....................................................................................................................... 6 
1.2 
Schema ......................................................................................................................... 8 
1.3 
Schedule of Activities (SoA) ....................................................................................... 9 
2. 
Introduction ................................................................................................................. 10 
2.1 
Study Rationale .......................................................................................................... 10 
2.2 
Background ................................................................................................................ 10 
2.3 
Benefit/Risk Assessment ........................................................................................... 11 
3. 
Objectives and Endpoints ........................................................................................... 11 
4. 
Study Design ................................................................................................................ 13 
4.1 
Overall Design ........................................................................................................... 13 
4.2 
Scientific Rationale for Study Design ....................................................................... 14 
4.3 
Justification for Dose of Active Treatment Groups ................................................... 14 
4.4 
End of Study Definition ............................................................................................. 14 
5. 
Study Population ......................................................................................................... 15 
5.1 
Inclusion Criteria ....................................................................................................... 15 
5.2 
Exclusion Criteria ...................................................................................................... 16 
5.3 
Lifestyle Considerations ............................................................................................ 17 
5.3.1 
Meals and Dietary Restrictions .............................................................................. 17 
5.3.2 
Caffeine and Alcohol .............................................................................................. 17 
5.4 
Screen Failures ........................................................................................................... 17 
5.5 
Run-in Failures .......................................................................................................... 18 
5.6 
Dropouts ..................................................................................................................... 18 
5.7 
General Procedures .................................................................................................... 18 
6. 
Study Intervention ...................................................................................................... 18 
6.1 
Study Intervention(s) Administered ........................................................................... 19 
6.1.1 
Study intervention assignment ............................................................................... 20 
6.1.2 
Participant Administration ...................................................................................... 20 
6.2 
Preparation/Handling/Storage/Accountability ........................................................... 21 
6.3 
Measures to Minimize Bias: Randomization and Blinding ....................................... 21 
6.3.1 
Unblinding .............................................................................................................. 22 
6.3.2 
Emergency unblinding by the investigator ............................................................. 22 
6.4 
Study Intervention Compliance ................................................................................. 22 
6.5 
Prior and Concomitant Therapy ................................................................................. 22 
6.5.1 
Rescue Medicine..................................................................................................... 23 
6.6 
Dose Modification ..................................................................................................... 23 
6.7 
Intervention after the End of the Study ...................................................................... 23 
7. 
Discontinuation of Study Intervention and Participant .......................................... 24 
7.1 
Discontinuation of Study Intervention ....................................................................... 24 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 4 of 54 
 
7.2 
Participant Discontinuation/Withdrawal from the Study ........................................... 24 
7.3 
Lost to Follow Up ...................................................................................................... 25 
8. 
Study Assessments and Procedures ........................................................................... 25 
8.1 
Efficacy Assessments ................................................................................................ 25 
8.1.1 
Screening Period ..................................................................................................... 25 
8.1.2 
Pre-surgery ............................................................................................................. 26 
8.1.3 
Impaction Score ...................................................................................................... 27 
8.1.4 
During Surgery ....................................................................................................... 27 
8.1.5 
Surgical Trauma Score ........................................................................................... 27 
8.1.6 
Postsurgery ............................................................................................................. 27 
8.2 
Safety Assessments .................................................................................................... 29 
8.2.1 
Physical Examinations ............................................................................................ 29 
8.2.2 
Vital Signs .............................................................................................................. 30 
8.2.3 
Clinical Safety Laboratory Assessments ................................................................ 30 
8.2.4 
Other Procedures and Variables ............................................................................. 30 
8.3 
Adverse Events and Serious Adverse Events ............................................................ 30 
8.3.1 
Time Period and Frequency for Collecting AE and SAE Information................... 30 
8.3.2 
Expected Adverse Events ....................................................................................... 31 
8.3.3 
Method of Detecting AEs and SAEs ...................................................................... 31 
8.3.4 
Follow-up of AEs and SAEs .................................................................................. 31 
8.3.5 
Regulatory Reporting Requirements for SAEs ...................................................... 31 
8.3.6 
Pregnancy ............................................................................................................... 32 
8.4 
Treatment of Overdose .............................................................................................. 32 
8.5 
Pharmacokinetics ....................................................................................................... 32 
8.6 
Pharmacodynamics .................................................................................................... 32 
8.7 
Genetics ..................................................................................................................... 32 
8.8 
Biomarkers ................................................................................................................. 33 
8.9 
Health Economics ...................................................................................................... 33 
9. 
Statistical Considerations ........................................................................................... 33 
9.1 
Statistical Hypotheses ................................................................................................ 33 
9.2 
Sample Size Determination ....................................................................................... 33 
9.3 
Populations for Analyses ........................................................................................... 34 
9.4 
Statistical Analyses .................................................................................................... 34 
9.4.1 
Efficacy Analyses ................................................................................................... 34 
9.4.2 
Safety Analyses ...................................................................................................... 37 
9.5 
Interim Analyses ........................................................................................................ 37 
10. Supporting Documentation and Operational Considerations ................................ 37 
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations .................... 37 
10.1.1 Regulatory and Ethical Considerations .................................................................. 37 
10.1.2 Financial Disclosure ............................................................................................... 38 
10.1.3 Funding ................................................................................................................... 38 
10.1.4 Informed Consent Process ...................................................................................... 38 
10.1.5 Data Protection and Confidentiality ....................................................................... 39 
10.1.6 Dissemination of Clinical Study Data .................................................................... 40 
10.1.7 Data Handling and Quality Assurance ................................................................... 40 
10.1.8 Source Documents .................................................................................................. 41 
10.1.9 Study and Site Closure ........................................................................................... 41 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 5 of 54 
 
10.1.10 Audit and Inspection ............................................................................................... 41 
10.1.11 Publication Policy ................................................................................................... 42 
10.2 Appendix 2: Clinical Laboratory Tests ...................................................................... 42 
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting .......................................................................................... 42 
10.3.1 Definition of AE ..................................................................................................... 42 
10.3.2 Definition of SAE ................................................................................................... 43 
10.3.3 Recording and Follow-Up of AE and/or SAE ........................................................ 45 
10.3.4 Reporting of SAEs .................................................................................................. 48 
10.4 Appendix 4: Contraceptive Guidance ........................................................................ 49 
10.5 Appendix 5: Participant Assessments ........................................................................ 51 
10.6 Appendix 6: Abbreviations ........................................................................................ 53 
11. References .................................................................................................................... 54 
 
Table of Tables 
Table 1 – Treatments administered .......................................................................................... 19 
Table 2 – Identity of study treatment ....................................................................................... 19 
 
Table of Figures 
Figure 1 – Design Overview ...................................................................................................... 8 
 
 
 
 
 
 
 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 6 of 54 
 
1. 
Protocol Summary 
1.1 
Synopsis 
Naproxen sodium and Hydrocodone/Acetaminophen are two widely used analgesics for acute 
pain.  In light of the concern with overuse of opioids, a comparison of the analgesic 
effectiveness of these two commercially available medications provides clinicians with 
important information to help them select an appropriate analgesic for their patient with acute 
pain.   
  
The post-impaction dental pain model has been widely used in the evaluation of OTC and 
prescription analgesics for a number of reasons. Dental surgical procedures can be easily 
standardized, and the population of participants undergoing a given procedure is usually 
relatively healthy and homogeneous. In addition, there is extensive data substantiating the 
usefulness of the dental pain model in predicting the relative efficacy of a wide range of 
analgesic medications. The model has been found to be very useful for comparing several 
measures of analgesic efficacy, including onset, peak effect, and duration of analgesic activity 
(Cooper, 2010, Cooper 1976, Kleinert, 2008).  This study will use the dental pain model to 
examine an OTC NSAID to a commonly prescribed oral opioid combination analgesic. 
Protocol Title: A Randomized, Double-Blind, Placebo-Controlled Trial to Compare the 
Analgesic Efficacy and Safety of Naproxen Sodium Tablets and 
Hydrocodone/Acetaminophen Tablets in Postsurgical Dental Pain  
Rationale: 
 
 
Both naproxen sodium and hydrocodone/acetaminophen are widely used analgesics.    
However, the relative efficacy of over-the-counter naproxen sodium has not been compared to 
hydrocodone/acetaminophen for relief of acute pain.   This is important because clinicians 
need to weigh the risks and benefits of available analgesic medications when selecting an 
appropriate analgesic to manage their patients complaints of acute pain. 
 
 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 7 of 54 
 
Objectives and Endpoints: 
 
Overall Design: 
This is a single center, randomized, double-blind, parallel, placebo-controlled study, stratified 
by baseline pain, in participants experiencing moderate to severe postoperative dental pain. 
The study will consist of a Prescreening telephone call, a Screening Visit, a one day 
Treatment Period and a Post-Operative visit.  Eligible participants who have undergone 
surgical extraction of three or four third molars, 2 of which must be mandibular partial or full 
bony impacted third molars will be randomized into one of three treatment groups and kept 
in-house and evaluated for efficacy and safety at the study center through completion of all 
trial procedures. 
Disclosure Statement: This is a parallel group treatment study with 3 arms that is participant 
and investigator blinded. 
Intervention Model: Parallel 
Primary Purpose: Treatment 
Number of Arms: 3 
Masking: No masking 
Number of Participants:  
Approximately 300 participants will be screened to achieve 220 randomly assigned to study 
intervention and 200 evaluable participants for an estimated total of 80 evaluable participants 
per active intervention group (total of 2 groups) and 40 for placebo. 
Intervention Groups and Duration: 
Participants will receive a single dose of study intervention of either naproxen sodium 440 
mg, hydrocodone/acetaminophen 10/650 mg, or placebo with pain and pain relief assessments 
performed over the next 12 hours. 
Objectives 
Endpoints 
Primary 
 
• 
To compare the analgesic efficacy of a single 
oral dose of naproxen sodium 440  mg (2 x 
220 mg tablets)  relative to 
hydrocodone/acetaminophen 10/650 mg (2 x 
5/325 mg tablets)  and placebo in participants 
experiencing moderate to severe post-
impaction surgery dental pain. 
• Sum of Pain Intensity Difference over 12 hours 
(SPID 0-12)  
Secondary 
 
• 
To compare the amount of pain relief 
produced by  a single oral dose of naproxen 
sodium 440  mg (2 x 220 mg tablets)  relative 
to hydrocodone/acetaminophen 10/650 mg (2 
x 5/325 mg tablets) and placebo in participants 
experiencing moderate to severe post-
impaction surgery dental pain. 
• Total Pain Relief over 12 hours (TOTPAR 0-12) 
• Total Pain Relief over 6 hours (TOTPAR 0-6) 
• Sum of Pain Intensity Difference over 6 hours 
(SPID 0-6) 
• Time to first use of rescue medication 
• Duration of Pain at Least Half Gone 
• Duration of Pain at Least Half Gone over first 6 
hours 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 8 of 54 
 
Data Monitoring Committee: No 
 
1.2 
Schema 
Figure 1 – Design Overview 
 
Screening 
Phase 
Treatment Phase 
Follow up Phase 
Trial 
Days 
Day -28 to -1 
Day 1 
Pre-surgery 
Day 1 
Surgery 
Day 1 
Post-surgery 
Day 1 
2-5 days after 
discharge 
 
 
Check-in to 
study site     
(if needed) 
Surgical 
teeth 
extraction 
Categorical 
pain 
NRS pain 
Stopwatch method 
NRS pain           
Pain relief 
Pain half gone 
Global assessment 
Phone call or visit 
  
  
= randomized to either naproxen sodium 440 mg, hydrocodone/acetaminophen 10/650  mg or placebo  
 
 
  
  


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 9 of 54 
 
1.3 
Schedule of Activities (SoA) 
 
Protocol Activities 
Screening Visit    
(within 28 days prior 
to oral surgery) 
Dosing Period  
Inpatient 
End of 
Trial Call 
(2-5 days after 
discharge) 
Day 1 
Written Informed Consent 
x 
 
 
Inclusion/Exclusion Reviewed 
x 
x 
 
Medical/Medication History 
x 
x 
 
Physical and Oral Examination  
x 
 
 
Vital Signsa 
x 
x 
 
Urine  for Drug Screen 
x 
x 
 
Breath or saliva alcohol test 
x 
x 
 
Dental x-ray examination 
x 
 
 
Urine Pregnancy Test (if applicable) 
x 
x 
 
Admission to Unit  
 
x 
 
Oral surgery (between 0530 h and 1030 h) 
 
x 
 
Randomization Number Assigned 
 
x 
 
Investigational Product Administration                 
 
x 
 
Surgical Trauma Rating 
 
x 
 
Stop watch method (perceptible and meaningful relief) 
 
x 
 
Categorical Pain Rating Scaleb   
 
x 
 
Pain Intensity Numerical Rating Scale (NRS)c      
 
x 
 
Categorical Pain Relief Rating Scale c 
 
x 
 
Starting pain is at least ½ gonec 
 
x 
 
Global Assessment of Pain Relief d 
 
x 
 
Concomitant Medications  
 
x 
x 
Adverse Events Assessed 
x 
x 
x 
Discharge from Unit the evening of Day 1 
 
x 
 
a vital signs ( blood pressure, pulse rate, and respiration after sitting for at least 5 minutes).  On Day 1, vital signs are due pre-
operatively, post-surgery at 1 hour, and 12 hours after study medication dosing. 
b to be completed prior to dosing 
c Pain Intensity NRS to be completed at baseline (predose), and Pain Intensity NRS and Categorical Pain Relief will be assessed 0.5, 
1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours postdose.  If rescue occurs, scales/questions will be completed immediately each 
time rescue medication is taken 
 d assessment will be completed immediately before first rescue medication is taken or at 12 hours post-dose 
 
 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 10 of 54 
 
2. 
Introduction 
In addition to the information provided below, please also refer to the Aleve Drug Facts Label 
(DFL) and the hydrocodone/acetaminophen prescribing information for any additional data on 
these two analgesic products. 
 
Naproxen sodium and hydrocodone/acetaminophen are two widely used analgesics for control 
of postoperative pain.  Therefore, the purpose of this investigation is to use the post-impaction 
dental pain model to compare the analgesic efficacy of over-the-counter naproxen sodium and 
prescription hydrocodone/acetaminophen to assess the relative effectiveness and safety of 
these two analgesics. 
2.1 
Study Rationale 
Both naproxen sodium and Hydrocodone/Acetaminophen are widely used analgesics.  
However, the relative efficacy of over-the-counter dosing with naproxen sodium has not been 
compared to hydrocodone/acetaminophen for relief of acute pain.   This assessment is 
important and timely as options for reducing the use of opioid analgesics in postoperative pain 
control are highly desired. Understanding the relative efficacy and safety of alternative 
analgesics can provide clinicians with important information when they select appropriate 
analgesics for their patients. 
2.2 
Background 
Both naproxen sodium and hydrocodone/acetaminophen are indicated for relief of acute pain. 
Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits production 
of cyclo-oxygenase (COX). COX enzymes play a key role in the inflammatory response and 
the production of prostaglandins.  Specifically, COX-1 is expressed in the gastrointestinal 
epithelium, vascular endothelium and kidney, while COX-2 plays a role in induction of 
inflammation. COX-2 inhibition reduces prostaglandin synthesis, leading to pain relief. 
Naproxen sodium has a long elimination half-life, approximately 10–15 h (Brune 2007).  
Correspondingly, it has a long duration of action (Kiersch 1994) and requires only once or 
twice daily dosing.  Hydrocodone/acetaminophen is a combination of an opioid analgesic and 
non-opioid analgesic with different mechanisms of action.  Hydrocodone is a mu-receptor 
agonist whose site of action is principally within the central nervous system 
 
 prescribing information).  Despite its long history, acetaminophen’s 
mechanism of action is not fully understood but is believed to involve different and 
interrelated central pathways, including effects on prostaglandin production, and on 
serotonergic, opioid, nitric oxide and cannabinoid pathways (Sharma 2014).  Both 
hydrocodone and acetaminophen have a relatively short duration and half-lives of less than 4 
hours (
 prescribing information). 
Both naproxen sodium and hydrocodone/acetaminophen have a long marketing history.  In 
the United States, naproxen has been marketed as a prescription medication since 1976 under 
the brand name Naprosyn®.  Its sodium salt, naproxen sodium, was first sold under the trade 
name Anaprox® in 1980.  In 1994, the US FDA approved naproxen sodium tablets (using the 
brand name Aleve®), 220 mg for over-the-counter (OTC) use. Aleve is indicated for the 
temporary relief of minor aches and pains due to: minor pain of arthritis, muscular aches, 
backaches, menstrual cramps, headaches, toothaches, and the common cold.  It also 
temporarily reduces fever.  Hydrocodone/acetaminophen has been marketed by prescription 
CCI
CCI


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 11 of 54 
 
under the brand name Norco®.  As a prescription medication, it is indicated for the 
management of pain severe enough to require an opioid analgesic and for which alternative 
treatments are inadequate. 
 
2.3 
Benefit/Risk Assessment 
Participants who need to have third molar extraction will be solicited to participate in this study.  
Participants who consent to participate may benefit by receiving a medical exam, dental 
radiographs and no-cost surgical procedures for teeth extraction. Furthermore, post-surgical 
participants will be provided continuous nursing care for approximately 12 hours after surgery.  
Potential risks of the surgical procedure include pain, dry socket, infection, swelling, bleeding, 
trismus, and lip or tongue numbness.  Potential risks related to local anesthesia and mild 
sedation include paresthesia and drowsiness.  Participants who experience a treatment failure 
can have the option of taking a standard rescue medication commonly used for post-operative 
pain relief.  Potential study medication benefit will be relief of postsurgical pain which is highly 
prevalent following extraction of wisdom teeth.  Potential risks of a single dose of OTC and 
prescription study medication are low and described in the Drug Facts Label and Prescribing 
Information, respectively. 
 
During the study, participants will be closely monitored for evidence of adverse events.  
Weighing between the potential risks associated with the study, and given the ability to mitigate 
risks through close monitoring and routine peri-operative care, this study is considered 
clinically and ethically acceptable. 
More detailed information about the known and expected benefits and risks and reasonably 
expected adverse events may be found in the naproxen sodium Investigator’s Brochure, 
 prescribing information and Aleve® Drug Facts Label. 
3. 
Objectives and Endpoints 
 
 
Objectives 
Endpoints 
Primary 
 
• 
To compare the analgesic efficacy of a 
single oral dose of naproxen sodium 440  
mg (2 x 220 mg tablets)  relative to 
hydrocodone/acetaminophen 10/650 mg (2 
x 5/325 mg tablets)  and placebo in 
participants experiencing moderate to 
severe post-impaction surgery dental pain. 
• 
Sum of Pain Intensity Difference over 12 
hours (SPID 0-12)  
CCI


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 12 of 54 
 
Objectives 
Endpoints 
Secondary 
 
• 
To compare the amount of pain relief 
produced by  a single oral dose of naproxen 
sodium 440  mg (2 x 220 mg tablets)  
relative to hydrocodone/acetaminophen 
10/650 mg (2 x 5/325 mg tablets) and 
placebo in participants experiencing 
moderate to severe post-impaction surgery 
dental pain. 
• 
To compare the time to first use of rescue 
medication of a single oral dose of 
naproxen sodium 440  mg (2 x 220 mg 
tablets) relative to 
hydrocodone/acetaminophen 10/650 mg (2 
x 5/325 mg tablets)  and placebo in 
participants experiencing moderate to 
severe post-impaction surgery dental pain 
• 
To compare the duration of pain intensity at 
least half gone for each timepoint of a 
single oral dose of naproxen sodium 440  
mg (2 x 220 mg tablets) relative to 
hydrocodone/acetaminophen 10/650 mg (2 
x 5/325 mg tablets) and placebo in 
participants experiencing moderate to 
severe post-impaction surgery dental pain 
• 
Total Pain Relief over 12 hours (TOTPAR 0-12) 
• 
Total Pain Relief over 6 hours (TOTPAR 0-6) 
• 
Sum of Pain Intensity Difference over 6 hours 
(SPID 0-6) 
• 
Time to first use of rescue medication over 12 
hours 
• 
Duration of Pain at Least Half Gone over 12 hours 
• 
Duration of Pain at Least Half Gone over first 6 
hours 
Other pre-specified 
 
To compare the following parameters of a single oral 
dose of naproxen sodium 440  mg (2 x 220 mg 
tablets) relative to hydrocodone/acetaminophen 
10/650 mg (2 x 5/325 mg tablets) and placebo in 
participants experiencing moderate to severe post-
impaction surgery dental pain: 
• 
Summed Pain Intensity Difference 
• 
Total pain relief  
• 
Pain Intensity Difference (PID) 
• 
Proportion/percent of participants with Pain 
Half Gone 
• 
Global assessment of the investigational 
product 
To compare the incidence of GI and Nervous system 
side effects produced by a single oral dose of 
naproxen sodium 440  mg (2 x 220 mg tablets)  
relative to hydrocodone/acetaminophen 10/650 mg 
(2 x 5/325 mg tablets) and placebo   
• 
The SPID0-4, 0-8 and 8-12  
• 
TOTPAR0-4, 0-8 and 8-12  
• 
Pain Intensity Difference (PID) and Pain Relief 
scores at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 
and 12 hours post-dose 
• 
Time to first perceptible relief measured by a 
stopwatch, time to meaningful relief measured by a 
stopwatch, and time to first perceptible relief 
confirmed by meaningful relief defined as the time 
to perceptible pain relief (the first stopwatch time) 
for those subjects who had meaningful pain relief 
(the second stopwatch time)  
• 
The cumulative proportion of subjects taking 
rescue medication over the 12 hour period. 
• 
Peak PID and peak pain relief  
• 
Percent of participants with Pain Half Gone at least 
once over 12 hours  
• 
Percent of participants with Pain Half Gone at each 
time point over 12 hours  
• 
Proportion of participants with pain at least one-
half gone at each time point 
• 
Cumulative percent of subjects with Pain at least 
half gone will be plotted over time  
• 
Cumulative percent of subjects with ‘at least a 2-
point PID’ will be plotted over time  
• 
Global Assessment of the investigational product 
• 
Percent of subjects reporting GI and Nervous 
system AEs prior to use of rescue medication 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 13 of 54 
 
4. 
Study Design 
4.1 
Overall Design 
Design Overview 
This is a single center, randomized, double-blind, parallel, placebo-controlled study, stratified 
by baseline pain, in participants experiencing moderate to severe postoperative dental pain. 
The study will consist of a Prescreening telephone call, a Screening Visit, a one day 
Treatment Period and a Post-Operative visit.  Eligible participants who have undergone 
surgical extraction of three or four third molars, 2 of which were mandibular partial or full 
bony impacted third molars, will be kept in-house and evaluated for efficacy and safety at the 
study site through completion of all trial procedures. 
Qualified participants will then be randomized into one of three treatments. Approximately 
300 participants will be screened prior to surgery.  Approximately 220 will have surgery and 
approximately 200 will be randomized to a specific treatment. 
Screening Phase 
Eligible participants will be screened and selected up to 28 days prior to oral surgery and 
dosing with investigational product. 
Treatment Phase 
Following selection, qualified participants will enter the Treatment Phase and be scheduled 
for their surgical teeth extractions.  After completion of the surgical teeth extractions, 
participants will remain at the study site for observation. Participants with appropriate pain 
severity for randomization will then be stratified by baseline pain intensity and randomized 
into one of three (3) treatment groups.  Participants will rate their pain severity and pain relief 
over the next 12 hours.  Onset of analgesia will be measured using a two stopwatch approach. 
The first stopwatch will be used to capture the time when any pain relief is first perceived and 
in certain cases the second stopwatch will be used to capture the time when pain relief 
becomes meaningful to the participant.  After completion of all trial procedures, participants 
will be discharged from the study site. 
All participants are required to remain at the study center and complete all assessments 
regardless of rescue. 
Follow-Up Phase 
Participants will be evaluated at a post-operative visit/call approximately 2-5 days after 
discharge for follow up for any adverse events or medications not known at the time of 
treatment. 
 
The duration of each participant’s participation will be approximately 37 days. For an 
overview on the study design and study procedures (see Figure 1). 
 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 14 of 54 
 
4.2 
Scientific Rationale for Study Design 
The study is designed specifically to capture and measure the effectiveness and side effect 
profiles of naproxen sodium compared to hydrocodone/acetaminophen on acute post-surgical 
dental pain in healthy participants who could benefit from the administration of an analgesic 
medication. The molar impaction dental pain model has been widely studied with OTC and 
prescription pain medications; however, should a participant not get sufficient pain relief, then 
rescue medication approved for treating acute pain (e.g. , acetaminophen, tramadol etc.) may 
be requested.  
The post-impaction dental pain model has been widely used in the evaluation of OTC and 
prescription analgesics for a number of reasons. Dental surgical procedures can be easily 
standardized, and the population of participants undergoing a given procedure is usually 
relatively healthy and homogeneous. In addition, there are extensive data substantiating the 
usefulness of the dental pain model in predicting the relative efficacy of a wide range of 
analgesic medications. The model has been found to be very useful for comparing several 
measures of analgesic efficacy, including onset, peak effect, and duration of analgesic activity 
(Cooper, 2010, Cooper 1976, Kleinert, 2008).  
Time to onset will be measured using a double stopwatch method.  The double-stopwatch 
method for measuring first perceptible relief and meaningful relief was developed using the 
dental pain model (Desjardins 2002).  After ingesting the study medication, the participant is 
asked to depress a stopwatch button when first perceiving any relief (First Perceptible Relief).  
If and when this stopwatch is depressed, the participant is then given a second stopwatch and 
asked to depress the button when the relief is perceived as meaningful (Meaningful Relief). 
Using this method, onset to First Perceptible and Meaningful Relief can be quantified to the 
nearest minute. This method has been proven to be sensitive and reliable for measuring 
analgesic onset (Cooper 2010). 
The endpoints and study design are consistent with most recent Guidance by FDA and 
methods advocated by experts (Cooper 2016 and Singla 2014).  
4.3 
Justification for Dose of Active Treatment Groups 
Participants will receive a single dose of study intervention which is sufficient to provide an 
analgesic effect in participants who experience post-surgical dental pain. 
4.4 
End of Study Definition 
A participant is considered to have completed the study if he/she has completed all phases of 
the study including the last scheduled procedure shown in the Schedule of Activities.  Trial 
sites will have the option of either contacting participants within 2 to 5 days after surgery (by 
phone) or scheduling participants for an office appointment, depending on their standard of 
care policies, to assess the occurrence or persistence of AEs, any medications taken, and for 
adequate treatment and follow up.   
Primary completion 
The primary completion is defined as the date of the last visit of the last participant for the 
primary outcome. 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 15 of 54 
 
5. 
Study Population 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known 
as protocol waivers or exemptions, is not permitted. 
The subject population will consist of healthy individuals who are status post extraction of 
three or four third molars, 2 of which were mandibular partial or full bony impactions. 
 
5.1 
Inclusion Criteria 
Participants are eligible to be included in the study only if all of the following criteria apply: 
1. Healthy, ambulatory, male or female volunteers 18 to 40 years of age; 
2. Body mass index 18.5 to 35.0 kg/m2 inclusive as measured by the NIH BMI 
Calculator; 
3. Subjects will undergo surgical extraction of three or four third molars, two of which 
must be mandibular molars. Maxillary third molars may be removed regardless of 
impaction level.  The mandibular extractions must have a trauma rating of mild or 
moderate and meet one of the following scenarios: 
• two full bony impactions 
• two partial bony impactions 
• one full bony impaction in combination with one partial bony impaction 
Supernumerary teeth present may also be removed at the discretion of the oral surgeon; 
5. Have not taken any form of medication, nutritional supplements with analgesic 
properties (e.g. GABA, turmeric) or herbal supplements (i.e., St. John’s Wort) within 
5 days of admission (except for oral contraceptives, prophylactic antibiotics, 
multivitamin supplements, or other routine medications to treat benign conditions 
(such as antibiotics to treat acne), and agree not to take any medication (other than that 
provided to them) throughout the study;    
6. Female subjects of childbearing potential must: a) be using a medically acceptable 
form of birth control [e.g., hormonal contraceptives (oral, patch, injectable or vaginal 
ring), implantable device (implantable rod or intrauterine device), or a double 
barrier]for at least 1 month prior to screening (3 months on oral contraceptives); b) 
abstain from sexual intercourse for at least 1 month prior to screening; or c) participate 
exclusively in a same sex relationship for at least 1 month prior to screening.  In 
addition, female subjects of childbearing potential must have a negative pregnancy test 
at Screening and prior to study drug administration.  Female subjects of non-
childbearing potential must be amenorrheic for at least two years or have undergone 
surgical sterilization (i.e. tubal ligation/occlusion, hysterectomy and/or bilateral 
oophorectomy); 
7. Have not consumed alcoholic beverages, or foods and beverages containing caffeine 
(examples; coffee, tea, chocolate, and colas) after midnight prior to surgery and agree 
not to consume any of these foods or beverages throughout their stay at the study site;    


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 16 of 54 
 
8. Use of only short-acting local anesthetic (e.g., mepivacaine or lidocaine) 
preoperatively, with or without a vasoconstrictor and nitrous oxide at the discretion of 
the Investigator; 
9. Have moderate to severe postoperative pain on the Categorical Pain Intensity Scale (a 
score of at least 2 on a 4 point scale) and a score of ≥ 5 on the 0-10 pain intensity NRS 
within 4.5 hours postsurgery; 
10. Ability to understand and follow study-related instructions; 
11. Be willing and able to participate in all scheduled visits, treatment plan, and  trial 
procedures according to the clinical protocol; 
12. Capable of giving signed informed consent as described in Section 10.1.4 which 
includes compliance with the requirements and restrictions listed in the informed 
consent form (ICF) and in this protocol. 
5.2 
Exclusion Criteria  
Participants are excluded from the study if any of the following criteria apply: 
1. History of hypersensitivity to naproxen sodium, hydrocodone/acetaminophen, 
ibuprofen, NSAIDS, aspirin, similar pharmacological agents, local anesthetics, rescue 
medication or components of the investigational products; 
2. Evidence or history of clinically significant (in the judgment of the investigator) 
hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular (including 
hypertension), hepatic, psychiatric, neurologic diseases, or malignancies within the 
last 5 years;    
3. Subjects with the following medical conditions may be eligible at the discretion of the 
investigator: ADHD on a stable dose regimen of 
methylphenidate/(dextro)amphetamine for at least 6 months; subjects with 
hypothyroidism on a stable dose of synthetic thyroid hormone  for at least 6 months; 
4. Have received any form of  treatment in the form of medication for depression in the 
past 6 months or any form of psychotropic agent (including selective serotonin uptake 
inhibitors [SSRI] but excluding ADHD medications described above) within the last 6 
months; 
5. Relevant concomitant disease such as asthma (exercise induced asthma is permitted); 
6. Current or past history of gastrointestinal ulceration, gastrointestinal bleeding or other 
bleeding disorder(s); 
7. Acute illness or active local infection prior to surgery that can interfere with the 
conduct of the study in the judgment of the investigator; 
8. Use of any OTC or prescription medications with which the administration of 
naproxen, hydrocodone/acetaminophen, acetaminophen, ibuprofen, any other NSAID, 
(e.g., tramadol) or if a medication is contraindicated; 
9. Use of any medications within 5 days of surgery until discharge from the study site 
(except oral contraceptives, prophylactic antibiotics, synthetic thyroid hormones, 
methylphenidate or medications to treat benign conditions such as antibiotics to treat 
acne); 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 17 of 54 
 
10. Females who are planning to become pregnant, pregnant or lactating; 
11. Habituation to analgesic drugs including opioids (i.e., routine use of oral analgesics 5 
or more times per week for greater than 3 weeks within the past 2 years); 
12. Alcoholism or drug abuse within 2 years prior to the Screening Visit or routine 
consumption of 3 or more alcohol containing beverages per day; Alcohol containing  
beverages are defined as one beer (5%), one glass of wine (11%) and one shot (40%) 
hard liquor; 
13. Positive urine drug screen or alcohol test on day of surgery; 
14. Surgeon’s trauma rating of severe following surgery; 
15. Use of Nicotine containing products from midnight prior to surgery until discharge 
from the study site or longer if so directed by the oral surgeon; 
16. Member or first-degree relative of study staff or the Sponsor directly involved in the 
study; 
17. Unwilling or unable to comply with all requirements outlined in the protocol; 
18. Participants with a medical disorder, condition, or history of such that could impair the 
participant’s ability to participate or complete this trial in the opinion of the 
investigator; 
19. Previous enrollment in this study. 
 
5.3 
Lifestyle Considerations 
No lifestyle restrictions are required. 
 
5.3.1 
Meals and Dietary Restrictions 
Participants will be instructed not to consume food that contains caffeine after midnight prior 
to surgery. 
 
5.3.2 
Caffeine and Alcohol 
Participants will be instructed not to consume alcohol or beverages containing caffeine (e.g., 
coffee, tea, chocolate, and colas) products after midnight prior to surgery.   
 
5.4 
Screen Failures 
Screen failures are defined as participants who consent to participate in the clinical study but 
are not subsequently randomly assigned to study intervention. A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure to respond to queries 
from regulatory authorities. Minimal information includes demography, screen failure details, 
eligibility criteria, and any serious adverse event (SAE). 
Individuals who do not meet the criteria for participation in this study (screen failure) due to 
scheduling surgery may be rescreened.  A previous dental x-ray if taken during the original 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 18 of 54 
 
screening visit can be used when rescreened.  Rescreened participants should be assigned a 
new participant number. 
5.5 
Run-in Failures 
A participant who, for any reason terminates the study after surgery and prior to the start of 
study drug administration (e.g., not meeting pain threshold) is regarded as a “Run-in failure”. 
 
5.6 
Dropouts 
A participant who discontinues study participation prematurely for any reason is defined as a 
“dropout” if the participant has been randomized and administered at least one dose of study 
drug. 
 
5.7 
General Procedures 
In all cases, the reason for withdrawal must be recorded on the screening log and in the 
participant's medical records.  
The participant may object to the generation and processing of post-withdrawal data as 
specified in Section 10.1.6. 
Details for the premature termination of the study as a whole (or components thereof) are 
provided in Section 10.1.9 (Premature termination of the Study). 
 
6. 
Study Intervention 
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study participant according to 
the study protocol. 
The study center will dispense a single-dose of an assigned treatment within 4.5 hours post-
surgery.  The tablets and placebo will be administered  based on a computer-generated 
randomization schedule (section 6.1.1) and the severity of pain experienced (moderate or 
severe).  Subjects who characterize their pain severity as mild and have a NRS <5 will not 
receive treatment and will be discharged from the study site with a prescription for pain 
medication, if deemed safe, by an Investigator.   
 
 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 19 of 54 
 
6.1 
Study Intervention(s) Administered 
Table 1 – Treatments administered 
Treatment (condition) 
Dose / route 
Amount / form 
Frequency of 
administration 
Naproxen sodium 440 mg (postsurgery) 
220 mg / orally 
2 / tablets 
single dose 
Hydrocodone/Acetaminophen 10/650 mg 
(postsurgery) 
5/325 mg / orally 
2 / tablets 
single dose 
Placebo (postsurgery) 
NA / orally 
2 / tablets 
single dose 
 
Table 2 – Identity of study treatment 
Treatment               
(UI number) 
Naproxen             
 
Hydrocodone/Acetaminophen 
Placebo                 
  
Dose 
two  tablets 
two tablets 
two  tablets 
Pharmaceutical 
Form 
tablet 
tablet 
tablet 
Strength 
220 mg 
5/325 mg 
not applicable 
Formulation 
naproxen sodium 
FD&C blue #2 lake 
hypromellose 
magnesium stearate 
microcrystalline cellulose 
polyethylene glycol 
povidone 
talc 
titanium dioxide 
hydrocodone bitartrate 
acetaminophen 
colloidal silicon dioxide 
crospovidone 
magnesium stearate 
microcrystalline cellulose 
povidone 
pregelatinized starch 
stearic acid 
dibasic calcium 
phosphate dihydrate 
magnesium stearate 
microcrystalline cellulose 
Route of 
administration 
orally with a full glass of 
water (i.e. about 8 ounces 
or 240 mL) 
orally with a full glass of    
water (i.e. about 8 ounces        
or 240 mL) 
orally with a full glass of 
water (i.e. about 8 ounces 
or 240 mL) 
Batch Number 
see study file 
see study file 
see study file 
Trade Name  and 
Manufacturer 
Aleve® 
Bayer                    
Bitterfeld, Germany 
 
        
 
 
Bayer  
Morristown, NJ USA 
 
All study drugs will be labeled according to the requirements of local law and legislation.  
Label text will be approved according to the sponsor’s agreed procedures, and a copy of the 
labels will be made available to the study site upon request. 
 
For all study drugs, a system of numbering in accordance with all requirements of Good 
Manufacturing Practice (GMP) will be used, ensuring that each dose of study drug can be 
traced back to the respective bulk batch of the ingredients.  Lists linking all numbering levels 
will be maintained by the sponsor’s clinical supplies Quality Assurance (QA) group.  
A complete record of batch numbers and expiry dates of all investigational products as well as 
the labels will be maintained in the clinical supply file. 
CCI
CCI
CCI


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 20 of 54 
 
The source of test and reference products will be documented in the clinical supply file. 
 
6.1.1 
Study intervention assignment 
At the beginning of the first treatment period, after completion of the pre-treatment baseline 
procedures/assessments, subjects who meet the entry criteria will be sequentially assigned to a 
unique number in sequential order (randomization number, RNR) according to the 
randomization schedule 2:2:1 (naproxen sodium; hydrocodone/acetaminophen; placebo) 
prepared prior to the study.  
Subjects will be numbered according to the following scheme: 
Whereas the “Xs” will be replaced with a four digit sequentially assigned number as each 
subject enters the study (e.g., first subject number will be 
 
The unique subject identifier number will be assigned in numerical order stratified by baseline 
2 or 3 categorical pain level (moderate or severe) prior to dosing (see Section 10.5).  Subjects 
who designate their baseline pain as moderate will use the lowest randomization number 
available with subsequent moderate randomizations using the next available lowest number.  
Subjects who designate their baseline pain as severe will use the highest randomization 
number available with subsequent severe randomizations using the next available highest 
randomization number.  Subjects who characterize their pain severity as mild and <5 on the 
NRS will not receive treatment and be withdrawn from the study. 
Once a number has been assigned to a subject, it cannot be reassigned to another subject.   
Subjects completing the Screening Visit, if not scheduled for surgery the same day,  will 
return to the trial site within 28 days, and if they continue to meet inclusion/exclusion criteria 
postsurgery will be randomized to one of three treatment groups: 
• Naproxen sodium tablets (220 mg x 2 tablets) 
• Hydrocodone/acetaminophen tablets (5/325 mg x 2 tablets) 
• Placebo tablets (2 tablets) 
Subjects will be assigned to treatment groups in accordance with the randomization schedule.  
The Sponsor will provide a randomization schedule to the study site. 
 
6.1.2 
Participant Administration 
Each participant will receive a single dose of the investigational medicinal product (IMP).  
Participants receive the IMP with a full glass of non-refrigerated, non-carbonated water (about 
8 ounces or 240 mL). Study intervention will be administered using dosing cups. Selection 
and preparation of the proper dose will be performed by an unblinded study team member 
using the provided randomization schedule (see Section 6.3).  The Investigator or a designee 
will supervise the study intervention administration in a manner which maintains the masking 
conditions (blinding of the subject).   
Participants should be NPO from midnight prior to surgery until completion of surgery, but, at 
the Investigator’s discretion must meet the American Society of Anesthesthesiology practice 
PPD
PPD


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 21 of 54 
 
guidelines for pre-operative fasting (ASA guideline, 2017).  Participants will continue fasting, 
with the exception of clear liquids, until after study drug administration. 
 
6.2 
Preparation/Handling/Storage/Accountability 
All study drugs will be labeled according to the requirements of local law and legislation.  
Label text will be approved according to the sponsor’s agreed procedures, and a copy of the 
labels will be made available to the study site upon request. 
For all study drugs, a system of numbering in accordance with all requirements of Good 
Manufacturing Practice (GMP) will be used, ensuring that each dose of study drug can be 
traced back to the respective bulk batch of the ingredients.  Lists linking all numbering levels 
will be maintained by the sponsor’s clinical supplies Quality Assurance (QA) group.  
A complete record of batch numbers and expiry dates of all investigational products as well as 
the labels will be maintained in the clinical supply file. 
The source of test and reference products will be documented in the clinical supply file. 
The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received and any discrepancies are 
reported and resolved before use of the study intervention.  Only participants enrolled in the 
study may receive study intervention and only authorized site staff may supply or administer 
study intervention. All study intervention must be stored in a secure, environmentally 
controlled, and monitored (manual or automated) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff.  The investigator, 
institution, or the head of the medical institution (where applicable) is responsible for study 
intervention accountability, reconciliation, and record maintenance (i.e., receipt, 
reconciliation, and final disposition records). 
The Sponsor will provide sufficient quantity of the IMP to the study site.  The study center 
will dispense IMP according to the randomization schedule and the subject’s categorical pain 
intensity (moderate or severe) post-surgery.  IMP will be supplied to the study center in multi-
dose bottles and dispensed by an unblinded member of the study team. 
All study drugs will be stored at the investigational site in accordance with GCP requirements 
and the instructions given by the clinical supplies department of the sponsor (or its 
affiliate/CRO), and will be inaccessible to unauthorized personnel. Special storage conditions 
and a complete record of batch numbers and expiry dates can be found in the Sponsor’s study 
file; the site-relevant elements of this information will be available in the investigator site file. 
On the day of receipt, the responsible site personnel will confirm receipt of study 
investigational products in writing. The personnel will use the study investigational products 
only within the framework of this clinical study and in accordance with this protocol. Receipt, 
distribution, return and destruction (if any) of the study drug must be properly documented 
according to the sponsor’s agreed and specified procedures. 
6.3 
Measures to Minimize Bias: Randomization and Blinding 
On Day 1 participants will be assigned a unique number (randomization number) in ascending 
numerical order at the study site. The randomization number encodes the participant’s 
assignment to one of the three (3) arms of the study, according to the randomization schedule 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 22 of 54 
 
generated prior to the study by the Sponsor. Each participant will be dispensed blinded study 
intervention, labeled with his/her unique randomization number, throughout the study. 
Participants enrolled in the trial, investigators and their staff involved in protocol procedures 
or who are involved in data collection, data entry and data analysis will be blinded to the 
identity of the treatments until the database is locked. The study monitor will conduct product 
accountability after database lock. To preserve blinding, participants will be blindfolded 
during administration of study medication.  Study drug will be dispensed by an unblinded 
study team member based on the randomization schedule.  That team member may have no 
other role in the study conduct and may not reveal the study drug’s identity to any members 
of the blinded study team. 
Sponsor will supply study medication in bulk containers.  Selection of the proper dose for an 
individual participant will be performed by an unblinded study team member using the 
provided randomization schedule.  The unblinded study team member will withdraw the 
appropriate study medication from the bulk container and transfer it to a dispensing cup.  The 
unblinded study team member will then bring the study medication to the treatment room 
where it will be dispensed to the participant by  the  study team member.  The unblinded 
study team member should have no other responsibilities in the study. 
 
6.3.1 
Unblinding 
In the case of a medical emergency, such as serious adverse events (SAE), breaking the blind 
may become necessary during the trial 
In compliance with applicable regulations, in the event of a serious unexpected adverse event 
(SUSAR) related to the blinded treatment, the participant’s treatment code will usually be 
unblinded before reporting to the health authorities, ethic committees and investigators (see 
Section 8.3.5). 
 
6.3.2 
Emergency unblinding by the investigator 
The investigator must report the blind break in conjunction with a SAE within 24 hours of 
becoming aware of the effect as defined in Section 10.3.1.  Participants who have been 
unblinded will not be included in the ITT or PP efficacy analysis. 
6.4 
Study Intervention Compliance 
The administration of the study medication will be supervised by an unblinded member of the 
Investigator’s team. This person will perform the oral cavity inspection after study drug 
administration and document that the participant receives the treatment as planned. 
6.5 
Prior and Concomitant Therapy 
The following treatments are prohibited from screening and during the study:  
 
• 
Use of any form of medication or herbal supplements, including GABA and 
turmeric, or curcumin,  within 5 days of surgery that would confound the 
evaluation of the study product, until discharge from the study site; 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 23 of 54 
 
• 
Use of acetaminophen, naproxen, hydrocodone/acetaminophen, ibuprofen, 
aspirin, or other NSAIDs or any other pain reliever (OTC or prescription) within 
5 days before surgery; 
• 
Use of alcoholic beverages, any food or beverages containing caffeine after 
midnight prior to surgery and throughout the evaluation period; 
All medications (prescription and nonprescription products, vitamin and herbal products) 
taken by the participant from 30 days prior to Screening to End of Trial (EOT) will be 
documented.  The reported medications will be reviewed and evaluated by the Principal 
Investigator or designee to determine if they affect the participant’s eligibility to participate in 
the study. 
 
6.5.1 
Rescue Medicine 
If adequate pain relief was not achieved, then participants are permitted to take rescue 
medication, although they will be encouraged to wait 90 minutes to allow the investigational 
product time to take effect.  The study site will supply the rescue medication that will be 
obtained locally.  Rescue medication, tramadol or other appropriate analgesic may be used at 
the discretion of the Investigator.  Participants will be required to complete pain assessments 
by rating pain intensity, pain relief and pain half gone at each time point and global assessment 
immediately before the initial dose of rescue medication.  All active stopwatch elapsed time(s) 
will be stopped at the time of rescue administration and recorded on the case report form. 
Rescue medication is also available on return of pain and the time of rescue medication will 
be recorded.  Pain assessments will be performed immediately before the first dose of rescue 
medication. 
• Rating of Pain Intensity (NRS); 
• Rating of Pain Relief (Categorical); 
• Pain Half Gone; 
• Global Assessment of investigational product as a pain reliever. 
Participants will be queried in a nonspecific fashion for any adverse events.  All observed and  
reported AEs will be collected and recorded on the case report form.  The information 
recorded will be based on signs and symptoms reported by the participant or observed by the 
research coordinator during clinical evaluation. 
6.6 
Dose Modification 
The dosing schedule cannot be modified. 
6.7 
Intervention after the End of the Study 
This study is a single dose administration after surgery and there is no additional treatment 
allocated.  Subjects who randomize into the study will be discharged from the study center 
after the final (12 hour post dosing) assessments, regardless of whether rescue medication had 
been taken or not. 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 24 of 54 
 
7. 
Discontinuation of Study Intervention and Participant  
 
7.1 
Discontinuation of Study Intervention  
See the SoA for data to be collected at the time of intervention discontinuation and follow-up 
and for any further evaluations that need to be completed. 
 
 
7.2 
Participant Discontinuation/Withdrawal from the Study 
Withdrawal criteria 
Participants must be withdrawn from the study if any of the following occurs: 
• A participant may withdraw from the study at any time at his/her own request, or may 
be withdrawn at any time at the discretion of the investigator for safety, behavioral, 
compliance, or administrative reasons. This is expected to be uncommon. 
• At the time of discontinuing from the study, if possible, an early discontinuation visit 
should be conducted, as shown in the SoA. See SoA for data to be collected at the 
time of study discontinuation and follow-up and for any further evaluations that need 
to be completed. 
• The participant will be permanently discontinued both from the study intervention and 
from the study at that time. 
• If the participant withdraws consent for disclosure of future information, the sponsor 
may retain and continue to use any data collected before such a withdrawal of consent. 
• Participant’s pain intensity post-surgery at pre-dose does not exceed ‘mild’ and the NRS 
is <5 (see Section 10.5); 
• If, in the Investigator's opinion, continuation of the study would be harmful to the 
participant's well-being; 
 
Participants may be withdrawn from the study if any of the following occurs: 
• Participant experiences one or more serious adverse events; 
• At the specific request of the Sponsor and in consultation with the Investigator (e.g., 
obvious non-compliance, safety concerns); 
• Protocol violation: if the participant develops conditions which would have prevented 
his/her entry into the study according to the inclusion/exclusion criteria, he/she must be 
withdrawn immediately if safety is concerned; in other cases, the investigator will 
decide whether there is a conflict with the study objectives. 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 25 of 54 
 
7.3 
Lost to Follow Up 
A participant will be considered lost to follow-up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site.  
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit: 
• The site must attempt to contact the participant and reschedule the missed visit as soon 
as possible and counsel the participant on the importance of maintaining the assigned 
visit schedule and ascertain whether or not the participant wishes to and/or should 
continue in the study. 
• Before a participant is deemed lost to follow up, the investigator or designee must 
make every effort to regain contact with the participant (where possible, 3 telephone 
calls and, if necessary, a certified letter to the participant’s last known mailing address 
or local equivalent methods). These contact attempts should be documented in the 
participant’s medical record. 
• Should the participant continue to be unreachable, he/she will be considered lost to 
follow up. 
8. 
Study Assessments and Procedures 
Study procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.  Immediate safety concerns should be discussed with the sponsor 
immediately upon occurrence or awareness to determine if the participant should continue or 
discontinue study intervention. Adherence to the study design requirements, including those 
specified in the SoA, is essential and required for study conduct. 
 
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.  
 
Procedures conducted as part of the participant’s routine clinical management (e.g., blood 
count) and obtained before signing of the ICF may be utilized for screening or baseline 
purposes provided the procedures met the protocol-specified criteria and were performed 
within the time frame defined in the SoA. 
 
8.1 
Efficacy Assessments 
If not stated otherwise, the measures / actions listed in the following Sections 8.1.1 to 8.1.6 
will be performed by a designated study team member as designated by the Principal 
Investigator. 
8.1.1 
Screening Period 
Note: No screening procedures may be performed unless participants have been 
provided an IRB-approved written informed consent which participants have read, 
understood, and signed.  
 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 26 of 54 
 
The Screening Period will be up to 28 days long.  The following will be determined during 
the Screening Visit: 
• Signed Informed Consent Form (ICF); 
• Review inclusion and exclusion criteria; 
• Participant demographics; 
• Medical/surgical history including history of drug, alcohol and tobacco use; 
• Medication history of all prescription, OTC products including vitamins or 
dietary/herbal supplements, taken during the past 30 days; 
• Vital signs consisting of sitting blood pressure, respiratory rate and pulse after sitting 
for at least 5 minutes; 
• Physical and oral examination; 
• Dental x-ray examination and interpretation including impaction score; 
Note: The medical interpretation may occur after the screening visit provided a 
diagnosis of impaction is determined prior to surgery. 
• Urine tests for illicit drugs; 
• Breath or saliva alcohol test; 
• Urine pregnancy test (if applicable). 
Upon satisfying the inclusion/exclusion criteria, eligible participants will be instructed to return 
to the trial site within 28 days for oral surgery.  Participants will be instructed to refrain from 
the use of all medications (prescription, nonprescription, herbal supplements) unless in the 
opinion of the Investigator or Sponsor, the medication will not interfere with study procedures, 
data integrity, or compromise the safety of the participants. 
Participants will be instructed not to consume alcohol, any food or beverages containing 
caffeine (e.g., coffee, tea, chocolate, and colas) products or use any nicotine containing products 
after midnight prior to surgery.  Surgery will be scheduled between 0530 h and 1030 h. 
The Principal Investigator or his/her designee must review participant’s study records before 
qualifying the participant for the trial. 
 
8.1.2 
Pre-surgery 
Participants are instructed to be nil per os (NPO) from midnight prior to surgery.  If a participant 
had something to eat or drink after midnight, the Investigator/designee must determine if 
surgery may proceed.  Participants will arrive at the unit at their assigned time and will have 
the following activities completed prior to dental surgery: 
• Review changes in the participant’s medical/medication history and 
inclusion/exclusion criteria since previous visit; 
• Urine tests for illicit drugs; 
• Breath or saliva alcohol test; 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 27 of 54 
 
• Vital signs (sitting blood pressure, pulse rate and respiration after sitting for 
5 minutes); 
• Urine pregnancy test (if applicable); 
• Review pain assessment process and procedures; 
 
8.1.3 
Impaction Score 
An Impaction Score will be used to assess each tooth based on the radiographic appearance and the 
intraoral examination.  Each tooth will be rated from 1 to 4 using the following criteria: 
(1) erupted in tissue (2) soft tissue impaction (3) partial bony impaction, and (4) full bony 
impaction.  Only participants whose mandibular impactions are scored (3) or (4) will be eligible to 
participate in the study. 
 
 
8.1.4 
During Surgery 
During surgery, participants will be administered a short acting local anesthetic (lidocaine or 
mepivacaine with or without vasoconstrictor) and nitrous oxide; at the discretion of the oral 
surgeon.  Topical anesthetics may also be used prior to the administration of the short acting 
local anesthetic.  Long duration local anesthetics like bupivacaine are not permitted.  No other 
perioperative analgesic or anesthetic agents are permitted. Perioperative corticosteroids are 
not permitted.  
 
8.1.5 
Surgical Trauma Score 
At the completion of the procedure, the surgeon will rate the degree of surgical trauma on a  
of (1) mild, (2) moderate or (3) severe.  Only individuals with a surgical trauma rating of mild 
(1) or moderate (2) will be eligible to participate in the study. 
 
8.1.6 
Postsurgery 
During the post-surgery recovery period, participants will rest quietly, but will be encouraged 
not to fall asleep.  Participants will be permitted to drink clear liquids following surgery.  
Participant may incorporate foods according to a soft diet following dosing beginning 60 
minutes after dosing.  Participants will not be allowed to eat 30 minutes prior to any planned 
assessments. 
In order to qualify for randomization and continue in the trial, participants must have 
‘moderate’ or ‘severe’ postoperative pain intensity on the Categorical Pain Rating Scale and a 
score of ≥ 5 on the NRS within 4.5 hours of the last suture. 
Eligible participants will be assigned a participant randomization number and investigational 
products will be administered according to a generated randomization schedule (see Section 
6.1.1). 
Participants who have not met the randomization criteria within 4.5 hours from last suture or 
14:30 h will not be randomized and may be discharged from the clinic, once deemed eligible 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 28 of 54 
 
by an Investigator. Prior to being released from the clinic, discharge procedures will be 
reviewed with the participant. When discharged, all participants will need to make prior 
arrangements for travel and should not drive themselves home. 
After the baseline (pre-dose) pain intensity is determined, pain intensity, pain relief and pain 
half  gone will be rated by participants at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 hours 
(+/-5 minutes) post-dose, and immediately prior to the use of the first dose rescue medication.   
Instructions will be provided for use of the two stopwatches.  A double-stopwatch method 
will be used to record time up to 12 hours after dosing for time to “first perceptible pain 
relief” (stopwatch A) and time to “meaningful pain relief determined” (stopwatch B). When 
the participant is administered study medication (following mouth inspection), the Study 
Coordinator or designee will start two stopwatches (one designated A and one designated B).  
The faces of the stopwatches will be covered so that the participant remains blinded to the 
exact time.  To determine the time when the participant begins to perceive pain relief, the 
participant will be given stopwatch A after dosing and will be instructed to:  
 
"Stop the stopwatch when you first begin to feel any pain-relieving effect whatsoever of the 
drug. That is, when you first feel a little relief. This does not necessarily mean that you feel 
completely better, although you might, but when you first feel any difference in the pain 
that you have now." 
 
The participant will notify the Study Coordinator as soon as this stopwatch is stopped. The 
elapsed time on stopwatch A will be recorded in the case report form as the time to first 
perceptible pain relief.  The participant will then be asked: 
 
"Do you consider the relief you experienced meaningful?"  
 
This answer will be recorded by the study coordinator in the case report form.  If the 
participant answers “Yes” to this question, then meaningful pain relief is confirmed.  The time 
recorded in the case report form for time to meaningful pain relief confirmed will be the 
same time recorded as first perceptible pain relief. The participant will not be given the 
second stopwatch. If the participant does not consider the relief to be meaningful, (by stating 
No), the participant will be given a second, covered stopwatch with instructions to: 
 
"Stop this stopwatch when you have meaningful relief, that is, when the relief from the 
pain is meaningful to you.” 
 
The elapsed time on stopwatch B will be recorded in the case report form as time to 
meaningful pain relief determined.  Unless meaningful pain relief is achieved, the 
participant will always have an active stopwatch in front of them.   
 
If the participant never experiences first perceptible pain relief, they will retain stopwatch A 
for the entire 12-hour evaluation period.  If the participant experiences first perceptible pain 
relief but not any meaningful pain relief (confirmed or determined), they will retain stopwatch 
B for the remainder of the 12-hour evaluation period. 
 
Participants will stay awake during the entire 12 hour assessment.  The order of the pain 
assessments is Pain Intensity, then Pain Relief, then Pain Half Gone then query about any AEs.  


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 29 of 54 
 
At hour 12 or immediately prior to the first dose of rescue medication (if prior to hour 12), study 
participants will be asked to provide a Global Assessment of investigational product after 
completion of the other assessments.  Additionally, participants will have vital signs taken after 
surgery then at 1 and 12 hours post-dose. 
 
Throughout the treatment period, the participants will be monitored for the occurrence of 
adverse events.  Symptoms will be assessed by spontaneous reporting of AEs and by asking the 
participants to respond to a non-leading question such as “How do you feel?” or “Are you 
experiencing any other effects?”  All reported or observed AEs will be collected and recorded 
on the case report form.  The information will be based on signs and symptoms reported by the 
participant or observed by the study personnel staff during clinical evaluation. 
 
If a participant has any clinically significant, trial-related abnormalities at the conclusion of the 
treatment period, the clinical monitor (or designated representative) should be notified and the 
participant should be asked to remain at the trial site until such abnormalities are stabilized or 
resolve.  If the participant is unable or unwilling to remain at the trial site, the clinical monitor 
(or designated representative) should be notified, and the Investigator should make every effort 
to arrange follow-up evaluations at appropriate intervals to document the course of the 
abnormalities. 
 
Participants will be allowed the use of ice following the use of rescue medication.  Ice will not 
be permitted for participants prior to randomization until after they have been administered 
rescue medication (if applicable).  If participant has been administered rescue, ice will be given 
as requested by the participant for 20 minute increments.  Ice will be removed 30 minutes prior 
to the completion of any pain assessments.  Upon completion of all trial procedures, participants 
will be discharged from the trial site.  Participants will need to make prior arrangements for 
travel and should not drive themselves home. 
8.2 
Safety Assessments  
Safety measures will be analyzed for all participants in the safety population.   
Adverse events will be collected throughout the treatment and safety follow-up periods and 
will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) dictionary.  
Only treatment-emergent AEs will be included, i.e., AEs that begin or worsen after the first 
dose of the investigational products in the treatment period.  The number and percent of 
participants who experience any event, by System Organ Class (SOC), and by Preferred Term 
will be displayed by treatment group.  Tables will also be produced by severity and 
relationship to investigational product. Seriousness, severity, relationship to investigational 
product, duration, and outcome will also be listed. 
Planned time points for all safety assessments are provided in the SoA. 
 
8.2.1 
Physical Examinations 
The physical examination (by means of inspection, palpation, auscultation) will be performed 
by qualified medical staff (e.g., a physician, oral surgeon, nurse practitioner or physician 
assistant) at the study site covering at least the organs of the head/neck, cardiovascular, and 
respiratory systems. 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 30 of 54 
 
Abnormal physical examination findings are recorded either as medical history or as adverse 
events (see Section 10.3.1). 
 
8.2.2 
Vital Signs 
Systolic and diastolic blood pressure and heart rate will be measured by a member of the 
investigator’s team under the following conditions: 
• Systolic blood pressure (after resting for at least 5 min in sitting position) 
• Diastolic blood pressure (after resting for at least 5 min in sitting position) 
• Heart rate (after resting for at least 5 min in sitting position) 
• Measuring site: cuff to be placed on the right / left upper arm (if possible, the same arm 
will be used for all measurements in one participant); cuff location will be documented 
• Method: oscillometric by automatic measurement device 
 
8.2.3 
Clinical Safety Laboratory Assessments 
Urine samples will be collected by a member of the investigator’s team, for time points and 
parameters see Section 1.3. 
 
8.2.4 
Other Procedures and Variables 
Eligible participants will undergo an oral examination and a dental x-ray (radiograph) exam to 
confirm that impacted third molar teeth are present. 
 
8.3 
Adverse Events and Serious Adverse Events 
The definitions of an AE or SAE can be found in Section 10.3. 
AE will be reported by the participant (or, when appropriate, by a caregiver, surrogate, or the 
participant's legally authorized representative or health care professional not involved in the 
study).  
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE. They remain responsible for 
following up SAEs, or AEs considered related to the study intervention or study procedures, 
or those that caused the participant to discontinue the study. 
 
8.3.1 
Time Period and Frequency for Collecting AE and SAE Information  
All AEs and SAEs will be collected from the signing of the ICF until the follow up visit at the 
time points specified in the SoA (Section 1.3). 
Medical occurrences that begin before the start of study intervention but after obtaining 
informed consent will be recorded on the Medical History/Current Medical Conditions 
section of the case report form (CRF) not the AE section. 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 31 of 54 
 
All SAEs will be recorded and reported to the sponsor or designee immediately and under no 
circumstances should this exceed 24 hours, as indicated in Section 10.3.2. The investigator 
will submit any updated SAE data to the sponsor within 24 hours of it being available. 
Investigators are not obligated to actively seek AE or SAE after conclusion of the study 
participation. However, if the investigator learns of any SAE, including a death, at any time 
after a participant has been discharged from the study, and he/she considers the event to be 
reasonably related to the study intervention or study participation, the investigator must 
promptly notify the sponsor. 
 
8.3.2 
Expected Adverse Events 
For this study, the applicable reference document is the most current version of the package 
insert for naproxen and prescribing information for Hydrocodone/Acetaminophen.  If relevant 
new safety information is identified, the information will be integrated into an update of the 
safety information and distributed to all participating sites. 
The expectedness of AEs will be determined by the sponsor according to the applicable 
reference document and according to all local regulations. 
 
8.3.3 
Method of Detecting AEs and SAEs 
The method of recording, evaluating, and assessing causality of AE and SAE and the 
procedures for completing and transmitting SAE reports are provided in Section 10.3. 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about AE 
occurrences.  
8.3.4 
Follow-up of AEs and SAEs 
After the initial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All SAEs will be followed until resolution, 
stabilization, the event is otherwise explained, or the participant is lost to follow-up (as 
defined in Section 7.3). Further information on follow-up procedures is given in Section 10.3.  
 
8.3.5 
Regulatory Reporting Requirements for SAEs 
Prompt notification by the investigator to the sponsor of an SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a 
study intervention under clinical investigation are met.  
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The 
sponsor will comply with country-specific regulatory requirements relating to safety reporting 
to the regulatory authority, Institutional Review Boards (IRB)/Independent Ethics 
Committees (IEC), and investigators. 
Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions (SUSAR) according to local regulatory requirements and sponsor policy and 
forwarded to investigators as necessary. 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 32 of 54 
 
An investigator who receives an investigator safety report describing an SAE or other specific 
safety information (e.g., summary or listing of SAEs) from the sponsor will review and then 
file it along with the Investigator’s Brochure and will notify the IRB/IEC, if appropriate 
according to local requirements.  Send the SAE CRF pages and complementary forms to: 
 or Fax: 
 (in the USA) 
 
8.3.6 
Pregnancy 
A participant’s participation is to be terminated immediately if a pregnancy is supposed 
(i.e. in case her pregnancy test becomes positive).   
The investigator must report to the sponsor any pregnancy occurring in a female study 
participant during her participation in this study.  The outcome of the pregnancy should be 
followed up carefully, and any outcome of the mother and the child at delivery should be 
reported.  Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs. 
For a pregnancy in the partner of a male study participant, all efforts will be made to obtain 
similar information on course and outcome, participant to the partner’s consent. 
For all reports, the forms provided are to be used.  The investigator should submit them within 
the same timelines as a SAE (see Section 8.3.5).  Send the completed pregnancy forms to: 
 or Fax: 
 (in the USA) 
8.4 
Treatment of Overdose 
For this study, any dose of study intervention greater than single dose study intervention 
within a 12-hour time period will be considered an overdose. 
The sponsor does not recommend specific treatment for an overdose. 
In the event of an overdose, the investigator/treating physician should: 
• Contact the Medical Monitor immediately; 
• Closely monitor the participant for any AE/SAE; 
• Document the quantity of the excess dose as well as the duration of the overdose in the 
CRF. 
8.5 
Pharmacokinetics 
Pharmacokinetic parameters are not evaluated in this study. 
 
8.6 
Pharmacodynamics 
Pharmacodynamic biomarker parameters are not evaluated in this study. 
 
8.7 
Genetics 
Genetic testing is not performed in this study. 
PPD
PPD
PPD
PPD


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 33 of 54 
 
8.8 
Biomarkers 
Biomarkers are not evaluated in this study. 
 
8.9 
Health Economics 
Health Economics/Medical Resource Utilization and Health Economics parameters are not 
evaluated in this study.  
9. 
Statistical Considerations 
Statistical analysis will be performed using statistical analysis software (SAS) and the version 
used will be specified in the Statistical Analysis Plan (SAP) and placed on file.  The SAP will 
contain a more comprehensive explanation than described below of the methodology used in 
the statistical analyses.  The SAP will also contain the rules and data handling conventions 
used to perform the analyses, and the procedure used for accounting for missing data. 
 
9.1 
Statistical Hypotheses 
The primary efficacy endpoint is the sum of change in pain intensity from 0 to 12 hours 
(SPID0-12). The treatment comparisons will be made in the following sequential order for 
SPID0-12 (each at 0.05 level of significance) in order to protect overall type 1 error at 0.05: 
• Naproxen sodium 440 mg versus Placebo  
• Naproxen sodium 440 mg versus hydrocodone/acetaminophen 10/650 mg 
• Hydrocodone/acetaminophen 10/650 mg versus Placebo 
Once a comparison is statistically non-significant, the subsequent comparisons will be 
technically ineligible to be declared significant.  However, all comparisons will be presented 
to provide a complete picture. 
 
9.2 
Sample Size Determination  
Assuming that the treatment difference of 12.3 and common standard deviation of 15.5 with 
respect to SPID0-12, a total of approximately 200 subjects (80 subjects per active treatment 
arm and 40 in the placebo using a 2:2:1 ratio) are required to achieve at least 90% of power 
with the type I error of 0.05, a total of  approximately 210 subjects will be randomized into 
the study if a drop-out rate of 5% is assumed. 
 
 
 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 34 of 54 
 
9.3 
Populations for Analyses  
For purposes of analysis, the following populations are defined: 
Population 
Description 
Safety 
All subjects who are randomized and take at least one 
dose of investigational product.  Safety measures will be 
analyzed for all subjects in the safety population. 
Intent-To-Treat (ITT) 
All subjects in the Safety Population who provide at least 
one pain assessment after the first dose of the 
investigational product.  ITT population will be used as 
secondary to conduct the sensitivity analysis for the 
selected parameters.   
Per Protocol (PP) Population 
PP population will include all subjects in ITT who do not 
have any major protocol violations and complete the 12 
hour assessments. PP population will be used as the 
primary analysis for the efficacy parameters. 
 
Major protocol deviations will be identified prior to 
database lock and may include but are not limited to 
significant violations of inclusion/exclusion criteria, 
noncompliance of the trial treatment taken, conditions 
such as vomiting and diarrhea or use of prohibited 
medications, and not following clinical trial protocol 
procedures.  Any subject who rescues or vomits at or 
prior to 60 minutes after ingesting study medication will 
be excluded from the PP population. 
 
9.4 
Statistical Analyses 
The statistical analysis plan (SAP) will be developed and finalized before database lock and 
will describe the subject populations to be included in the analyses, and procedures for 
accounting for missing, unused, and spurious data. This section is a summary of the planned 
statistical analyses of the primary and secondary endpoints. 
 
9.4.1 
Efficacy Analyses 
For each post-dose time point, Pain Intensity Differences (PID) will be derived by subtracting 
the pain intensity at the post-dose time point from the baseline intensity score (baseline score 
– post-baseline score).  A positive difference is indicative of improvement.  Time-weighted 
Sum of Pain Intensity Differences (SPIDs) will be calculated for 4, 6, 8, and 12 hours by 
multiplying the PID score at each post-dose time point by the duration (in hours) since the 
preceding time point and then summing these values over 4, 6, 8, and 12 hours, respectively.   
Similarly, Total Pain Relief Scores (TOTPARs), will be calculated by multiplying the pain 
relief score at each post-dose time point by the duration (in hours) since the preceding time 
point and then summing these values. 
In all analyses, for participants who take rescue medication, all pain intensity scores after 
intake of rescue medication will be imputed by the worse of the baseline or the score assessed 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 35 of 54 
 
immediately before taking rescue medication. All pain relief after intake of rescue medication 
will be imputed by “no relief” (0). All pain at least half gone after intake of rescue medication 
will be imputed by “NO”. 
 
Endpoint 
Statistical Analysis Methods 
Primary 
The primary efficacy analyses population will be based on the PP 
population. 
 
Sum of Pain Intensity Difference over 12 hours:  SPID0-12 be 
analyzed using an analysis of covariance model (ANCOVA) with 
treatment as fixed effect and baseline pain intensity score as the 
covariate.  A 95% of confidence interval (CI) for the treatment 
differences will be calculated based on the above mentioned model. 
Secondary 
Total Pain Relief over 12 hours:  TOTPAR0-12 will be analyzed 
similarly as for the primary endpoint. 
 
Total Pain Relief over 6 hours:  TOTPAR0-6 will be analyzed 
similarly as for the primary endpoint. 
 
Sum of Pain Intensity Difference over 12 hours:  SPID0-6 will be 
analyzed similarly as for the primary endpoint. 
 
Time to first use of rescue medication.  If a subject did not take the 
rescue medication during the treatment period, (s)he will be censored 
at the time of last assessment. Time to first use of rescue medication 
will be estimated and plotted using Kaplan-Meier method and 
analyzed using log-rank test stratified by baseline pain intensity. 
 
Duration of Pain at Least Half Gone and Duration of Pain Half 
Gone over the first 6 hours will be calculated by the time between 
the time point when pain at least half gone was firstly reported and 
the subsequent time point when pain at least half gone was firstly 
reversed or the time of last assessment if pain at least half gone was 
retained for all subsequent time points. The duration will be set to 0 
when no pain at least half gone was ever reported throughout the 
assessment period. This endpoint will be analyzed similarly as for the 
primary endpoint. 
  
 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 36 of 54 
 
Other pre-specified 
The SPID0-4, 0-8 and 8-12 will be analyzed using the same 
methodology as for SPID0-12. 
 
TOTPAR0-4, 0-8 and 8-12 will be analyzed using the same 
methodology as for SPID0-12. 
 
Pain Intensity Difference (PID) and Pain Relief scores at 0.5, 1, 1.5, 
2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 hours post-dose. Descriptive 
statistics for each time point and graphical illustrations of the time 
effect curves will be presented. 
 
Time to first perceptible relief measured by a stopwatch, time to 
meaningful relief measured by a stopwatch, and time to first 
perceptible relief confirmed by meaningful relief defined as the time 
to perceptible pain relief (the first stopwatch time) for those subjects 
who had meaningful pain relief (the second stopwatch time) will be 
analyzed similarly as for the time to first use of rescue medication.  
 
The cumulative proportion of subjects taking rescue medication over 
time will be analyzed using Chi-square tests and curves over time 
will be plotted.  Frequency tables will be tabulated for the number of 
times that the subject took rescue medication over the 12 hour period. 
 
Peak PID and peak pain relief will be analyzed descriptively. 
 
Percent of participants with Pain Half Gone at least once by 12 hours 
will be analyzed using Chi-square tests. 
 
Percent of participants with Pain Half Gone at each time point over 
12 hours will be analyzed using Chi-square tests. 
 
The proportion of participants with pain at least one-half gone at each 
time point will be summarized descriptively and plotted over time by 
treatment group. 
 
Cumulative percent of subjects with Pain at least half gone will be 
plotted over time and will be analyzed using Chi-square tests. 
 
Cumulative percent of subjects with ‘at least a 2-point PID’ will be 
plotted over time and will be analyzed using Chi-square tests. 
  
Global Assessment of the investigational product will be analyzed 
using CMH method with modified ridit score. 
 
Percent of subjects reporting GI and Nervous system Adverse Events 
prior to use of rescue medication. 
 
 
 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 37 of 54 
 
9.4.2 
Safety Analyses 
All safety analyses will be performed on the Safety Population.  
Endpoint 
Statistical Analysis Methods 
Secondary 
AEs produced by severity and relationship to each IMP. 
Seriousness, severity, relationship to each IMP duration, and 
outcome will also be listed. 
 
Quantitative data for blood pressure, heart rate, body weight, body 
temperature will be described by summary statistics for the original 
data as well as for the change from baseline.  Frequency tables will 
be provided for qualitative data. Laboratory data outside the 
reference range will be listed and highlighted with ‘L’ for low and 
‘H’ for high. An additional table with all abnormal values will be 
presented. 
 
9.5 
Interim Analyses  
No interim analysis will be performed. 
10. 
Supporting Documentation and Operational Considerations 
10.1 
Appendix 1: Regulatory, Ethical, and Study Oversight Considerations 
 
10.1.1 
Regulatory and Ethical Considerations 
• This study will be conducted in accordance with the protocol and with the following: 
o Consensus ethical principles derived from international guidelines including 
the Declaration of Helsinki and Council for International Organizations of 
Medical Sciences (CIOMS) International Ethical Guidelines 
o Applicable ICH Good Clinical Practice (GCP) Guidelines 
o Applicable laws and regulations 
• The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant 
documents (e.g., advertisements) must be submitted to an IRB/IEC by the investigator 
and reviewed and approved by the IRB/IEC before the study is initiated.  
• Any amendments to the protocol will require IRB/IEC approval before 
implementation of changes made to the study design, except for changes necessary to 
eliminate an immediate hazard to study participants.  
• The investigator will be responsible for the following: 
o Providing written summaries of the status of the study to the IRB/IEC annually 
or more frequently in accordance with the requirements, policies, and 
procedures established by the IRB/IEC 
o Notifying the IRB/IEC of SAEs or other significant safety findings as required 
by IRB/IEC procedures 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 38 of 54 
 
o Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 
536/2014 for clinical studies (if applicable), and all other applicable local 
regulations 
 
10.1.2 
Financial Disclosure 
Investigators and sub-investigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators 
are responsible for providing information on financial interests during the course of the study 
and for 1 year after completion of the study. 
 
10.1.3 
Funding 
This study will be funded by its sponsor. 
 
10.1.4 
Informed Consent Process 
All relevant information on the study will be summarized in an integrated participant 
information sheet and informed consent form provided by the sponsor or the study center.  
Sample participant information and informed consent/assent forms are provided as a 
document separate to this protocol. 
Based on this participant information sheet, the investigator or his/her representative will 
explain the nature of the study to the participant or his/her legally authorized representative 
and answer all questions regarding the study.  Participants must be informed that their 
participation is voluntary. Participants will be required to sign a statement of informed 
consent that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, Health 
Insurance Portability and Accountability Act (HIPAA) requirements, where applicable, and 
the IRB/IEC or study center. 
The investigator will also mention that written approval of the IRB has been obtained. 
Each participant will be informed about the following aspects of premature withdrawal: 
• Each participant has the right to withdraw from the study at any time without any 
disadvantage and without having to provide reasons for this decision;   
• The participant’s consent covers EOT examinations as specified in the visit description 
described in Section 7.2 to be conducted after withdrawal of consent; 
• The participant’s data that have been collected until the time of withdrawal will be 
retained and statistically analyzed in accordance with the statistical analysis plan; 
• Participant-specific data on the basis of material obtained before withdrawal may be 
generated after withdrawal (e.g., image reading, analysis of biological specimen such as 
blood, urine or tissues); these data would also be retained and statistically analyzed in 
accordance with the statistical analysis plan.  The participant has the right to object to the 
generation and processing of this post-withdrawal data.  For this, he/she needs to sign a 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 39 of 54 
 
corresponding declaration of objection; alternatively, the participant’s oral objection may 
be documented in the participant’s source data. 
Each participant will have ample time and opportunity to ask questions. 
Only if the participant agrees to sign the informed consent form and has done so, may he/she 
enter the study.  Additionally, the investigator will personally sign and date the form.  The 
participant will receive a copy of the signed and dated form. 
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date the written consent was obtained. 
The authorized person obtaining the informed consent must also sign the ICF.  In the event 
that informed consent is obtained on the date that baseline study procedures are performed, 
the study record or participant´s clinical record must clearly show that informed consent was 
obtained prior to these procedures. 
For minors or adults under legal protection, consent shall be given by the legal guardian(s). 
The consent of a minor or adult under legal protection shall also be requested where such a 
person is able to express his/her own will. His/her refusal or the withdrawal of his/her consent 
may not be disregarded. 
The informed consent form and any other written information provided to participants will be 
revised whenever important new information becomes available that may be relevant to the 
participant’s consent, or there is an amendment to the protocol that necessitates a change to 
the content of the participant information and / or the written informed consent form.  The 
investigator will inform the participant of changes in a timely manner and will ask the 
participant to confirm his/her participation in the study by signing the revised informed 
consent form.  Any revised written informed consent form and written information must 
receive the IRB`s approval / favorable opinion in advance of use. 
Participants who are rescreened are required to sign a new ICF. 
 
10.1.5 
Data Protection and Confidentiality 
Any participant records or datasets that are transferred to the sponsor will contain the 
identifier only; participant names or any information which would make the participant 
identifiable will not be transferred.  The participant must be informed that his/her personal 
study-related data will be used by the sponsor in accordance with local data protection law. 
The level of disclosure must also be explained to the participant.  The participant must be 
informed that his/her medical records may be examined by Clinical Quality Assurance 
auditors or other authorized personnel appointed by the sponsor, by appropriate IRB/IEC 
members, and by inspectors from national or international regulatory authorities. 
All records identifying the participant will be kept confidential and, to the extent permitted by 
the applicable laws and/or regulations, will not be made publicly available. 
Participant names will not be supplied to the sponsor.  Only the participant numbers (SNR 
and RNR) will be recorded in the CRF/eCRF data collection system, and if the participant 
name appears on any other document (e.g., pathologist report), it must be obliterated before a 
copy of the document is supplied to the sponsor.  Study findings stored on a computer will be 
stored in accordance with local data protection laws.  As part of the informed consent process, 
the participants will be informed in writing that representatives of the sponsor, IRB, or 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 40 of 54 
 
regulatory authorities may inspect their medical records to verify the information collected, 
and that all personal information made available for inspection will be handled in strictest 
confidence and in accordance with local data protection laws. 
If the results of the study are published, the participant’s identity will remain confidential. 
The investigator will maintain a list to enable participants to be identified. 
 
10.1.6 
Dissemination of Clinical Study Data 
The sponsor will make the information regarding the study publicly available on the internet 
at www.clinicaltrials.gov as applicable to local regulations. 
All data and results and all intellectual property rights in the data and results derived from the 
study will be the property of the sponsor who may utilize them in various ways, such as for 
submission to government regulatory authorities or disclosure to other investigators. 
Regarding public disclosure of study results, the sponsor will fulfill its obligations according 
to all applicable laws and regulations.  The sponsor is interested in the publication of the 
results of every study it performs.  
 
10.1.7 
Data Handling and Quality Assurance 
The data collection tool for this study will be a validated electronic data capture system to be 
used at the study site. Participant data necessary for analysis and reporting will be provided to 
the Sponsor in CDISC (Clinical Data Interchange Standards Consortium) standards. 
Clinical data management will be performed in accordance with applicable sponsor’s/CRO’s 
standards and data cleaning procedures.  This is applicable for data recorded on the 
CRF/eCRF data collection system as well as for data from other sources (e.g., laboratory). 
For data coding (e.g., AEs, medication), internationally recognized and accepted dictionaries 
will be used. 
Reasons for missing data, especially inability to perform a test, must be documented. 
All participant data relating to the study, except operative medications will be recorded on a 
CRF/eCRF data collection system unless transmitted to the sponsor or designee electronically 
(e.g., laboratory data). The investigator is responsible for verifying that data entries are 
accurate and correct by physically or electronically signing the CRF.  
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.  
The investigator must permit study-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.  
Monitoring details describing strategy (e.g., risk-based initiatives in operations and quality 
such as Risk Management and Mitigation Strategies and Analytical Risk-Based Monitoring), 
methods, responsibilities and requirements, including handling of noncompliance issues and 
monitoring techniques are provided in the monitoring plan or applicable monitoring SOP. 
The sponsor or designee is responsible for the data management of this study including 
quality checking of the data.  


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 41 of 54 
 
The sponsor assumes accountability for actions delegated to other individuals (e.g., Contract 
Research Organizations). 
Study monitors will perform ongoing source data verification to confirm that data entered into 
the CRF by authorized site personnel are accurate, complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study is 
being conducted in accordance with the currently approved protocol and any other study 
agreements, ICH GCP, and all applicable regulatory requirements.  
Records and documents, including signed ICFs, pertaining to the conduct of this study must 
be retained by the investigator for 10 years (US), 25 years (Canada) after study completion 
unless local regulations or institutional policies require a longer retention period. No records 
may be destroyed during the retention period without the written approval of the sponsor. No 
records may be transferred to another location or party without written notification to the 
sponsor.  
 
10.1.8 
Source Documents 
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the investigator’s site. 
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator may need to request previous medical records or transfer records, depending on 
the study. Also, current medical records must be available. 
10.1.9 
Study and Site Closure 
The sponsor designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies 
have been collected and a study-site closure visit has been performed. 
The investigator may initiate study-site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of a study site by the sponsor or investigator may include but are 
not limited to: 
• Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines 
• Inadequate recruitment of participants by the investigator 
• Discontinuation of further study intervention development 
 
10.1.10 
Audit and Inspection 
To ensure compliance with GCP and regulatory requirements, a member of the sponsor’s (or a 
designated CRO’s) quality assurance unit may arrange to conduct an audit to assess the 
performance of the study at the study site and of the study documents originating there.  The 
investigator/institution will be informed of the audit outcome. 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 42 of 54 
 
In addition, inspections by regulatory health authority representatives and IEC(s)/IRB(s) are 
possible.  The investigator should notify the sponsor immediately of any such inspection. 
The investigator/institution agrees to allow the auditor or inspector direct access to all relevant 
documents and allocate his/her time and the time of his/her staff to the auditor/inspector to 
discuss findings and any issues.  Audits and inspections may occur at any time during or after 
completion of the study. 
 
10.1.11 
Publication Policy 
The results of this study may be published or presented at scientific meetings. If this is 
foreseen, the investigator agrees to submit all manuscripts or abstracts to the sponsor before 
submission. This allows the sponsor to protect proprietary information and to provide 
comments.  
The sponsor will comply with the requirements for publication of study results. In accordance 
with standard editorial and ethical practice, the sponsor will generally support publication of 
multicenter studies only in their entirety and not as individual site data. In this case, a 
coordinating investigator will be designated by mutual agreement. 
Authorship will be determined by mutual agreement and in line with International Committee 
of Medical Journal Editors authorship requirements. 
 
10.2 
Appendix 2: Clinical Laboratory Tests 
Urine samples will be collected by a member of the investigator’s team, for time points and 
parameters see Section 1.3.  Additional tests may be performed at any time during the study as 
determined necessary by the investigator or required by local regulations. 
 
10.3 
Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting 
10.3.1 
Definition of AE  
 
AE Definition 
• An AE is any untoward medical occurrence in a patient or clinical study 
participant, associated with the use of study intervention, whether or not considered 
related to the study intervention. 
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) associated 
with the use of study intervention. 
 
Events Meeting the AE Definition  


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 43 of 54 
 
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) 
or other safety assessments (e.g., ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the investigator. 
• Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or intensity of the condition. 
• New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study. 
• Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction. 
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE/SAE unless it is an intentional overdose taken with possible suicidal/self-
harming intent. Such overdoses should be reported regardless of sequelae. 
•  “Lack of efficacy” or “failure of expected pharmacological action” per se will not 
be reported as an AE or SAE. Such instances will be captured in the efficacy 
assessments. However, the signs, symptoms, and/or clinical sequelae resulting 
from lack of efficacy will be reported as AE or SAE if they fulfil the definition of 
an AE or SAE.  
 
Events NOT Meeting the AE Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condition. 
• The disease/disorder being studied or expected progression, signs, or symptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition. 
• Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that 
leads to the procedure is the AE. 
• Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital). 
• Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) 
present or detected at the start of the study that do not worsen. 
 
10.3.2 
Definition of SAE 
An SAE is defined as any untoward medical occurrence that, at any dose: 
a. 
Results in death 
b. 
Is life-threatening 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 44 of 54 
 
• The term 'life-threatening' in the definition of 'serious' refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which hypothetically might have caused death, if it were more severe. 
c. 
Requires inpatient hospitalization or prolongation of existing hospitalization 
• In general, hospitalization signifies that the participant has been detained (usually 
involving at least an overnight stay) at the hospital or emergency ward for 
observation and/or treatment that would not have been appropriate in the 
physician’s office or outpatient setting. Complications that occur during 
hospitalization are AEs. If a complication prolongs hospitalization or fulfills any 
other serious criteria, the event is serious. When in doubt as to whether 
“hospitalization” occurred or was necessary, the AE should be considered serious. 
• Hospitalization for elective treatment of a pre-existing condition that did not 
worsen from baseline is not considered an AE. 
d. 
Results in persistent disability/incapacity 
• The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions. 
• This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (e.g., sprained ankle) which may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption. 
e. 
Is a congenital anomaly/birth defect 
f. 
Other situations: 
• Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediately life-threatening or result in death or hospitalization but 
may jeopardize the participant or may require medical or surgical intervention to 
prevent one of the other outcomes listed in the above definition. These events 
should usually be considered serious. 
• Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospitalization, or development of drug 
dependency or drug abuse. 
 
 
 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 45 of 54 
 
10.3.3 
Recording and Follow-Up of AE and/or SAE  
 
AE and SAE Recording 
• When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (e.g., hospital progress notes, laboratory reports, and diagnostics 
reports) related to the event. 
• The investigator will then record all relevant AE/SAE information in the CRF. 
• It is not acceptable for the investigator to send photocopies of the participant’s 
medical records in lieu of completion of the AE/SAE CRF page. 
• There may be instances when copies of medical records for certain cases are 
requested by the sponsor. In this case, all participant identifiers, with the exception 
of the participant number, will be redacted on the copies of the medical records 
before submission. 
• The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/symptoms) will be documented as the AE/SAE. 
Assessment of Intensity 
The investigator will make an assessment of intensity for each AE and SAE reported 
during the study and assign it to one of the following categories:  
• Mild: An event that is easily tolerated by the participant, causing minimal 
discomfort and not interfering with everyday activities. 
• Moderate: An event that causes sufficient discomfort and interferes with normal 
everyday activities. 
• Severe: An event that prevents normal everyday activities. An AE that is assessed 
as severe should not be confused with an SAE. Severe is a category utilized for 
rating the intensity of an event; and both AEs and SAEs can be assessed as severe. 
• An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes 
as described in the definition of an SAE, NOT when it is rated as severe. 
Assessment of Causality 
• The investigator is obligated to assess the relationship between study intervention 
and each occurrence of each AE/SAE. 
• A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out. 
• Possible answers are “yes” or “no” 
• An assessment of “no” would include: 
o The existence of a highly likely alternative explanation, e.g., mechanical 
bleeding at surgical site. 
or 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 46 of 54 
 
o Non-plausibility, e.g., the participant is struck by an automobile when there 
is no indication that the drug caused disorientation that may have caused 
the event; cancer developing a few days after the first drug administration. 
An assessment of “yes” indicates that that the AE is reasonably associated with the use of 
the study treatment. 
• The investigator will use clinical judgment to determine the relationship. 
• Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study intervention 
administration will be considered and investigated. 
• The investigator will also consult the Investigator’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment. 
• For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality. 
• There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report. However, it is very important 
that the investigator always make an assessment of causality for every event 
before the initial transmission of the SAE data. 
• The investigator may change his/her opinion of causality in light of follow-up 
information and send an SAE follow-up report with the updated causality 
assessment. 
• The causality assessment is one of the criteria used when determining regulatory 
reporting requirements. 
Causal relationship to protocol-required procedure(s) 
The assessment of a possible causal relationship between the AE and protocol-required 
procedure(s) is based on the question whether there was a “reasonable causal relationship” 
to protocol-required procedure(s). 
Possible answers are “yes” or “no” 
Action taken with study intervention 
Any action on study treatment to resolve the AE is to be documented using the categories 
listed below. 
The study treatment action should be recorded separately for each study treatment as 
detailed in the CRF/eCRF data collection system. 
• Drug withdrawn 
• Drug interrupted 
• Not applicable 
• Unknown 
 
 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 47 of 54 
 
Other specific treatment(s) of adverse event 
• None 
• Remedial drug therapy 
• Other 
Outcome of adverse event 
The outcome of the AE is to be documented as follows:  
• Recovered/resolved 
• Recovering/resolving 
• Recovered/resolved with sequelae 
• Not recovered/not resolved 
• Fatal 
• Unknown 
Follow-up of AEs and SAEs 
• The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated to elucidate the nature 
and/or causality of the AE or SAE as fully as possible. This may include additional 
laboratory tests or investigations, histopathological examinations, or consultation 
with other health care professionals. 
• New or updated information will be recorded in the originally completed CRF. 
• The investigator will submit any updated SAE data to the sponsor within 24 hours 
of receipt of the information. 
 
 
 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 48 of 54 
 
10.3.4 
Reporting of SAEs 
 
SAE Reporting to the Sponsor via Paper CRF/Complementary pages 
• 
Email or facsimile transmission of the SAE paper CRF as well as the 
complementary pages provided is the preferred method to transmit this 
information to the Bayer’s Pharmacovigilance department (see Section 
8.3.5). 
• 
In rare circumstances and in the absence of facsimile equipment, 
notification by telephone is acceptable with a copy of the SAE data 
collection tool sent by overnight mail or courier service. 
• 
Initial notification via telephone does not replace the need for the 
investigator to complete and sign the SAE CRF and complementary 
pages within the designated reporting time frames. 
 
 
 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 49 of 54 
 
10.4 
Appendix 4: Contraceptive Guidance 
Definitions: 
Woman of Childbearing Potential (WOCBP) 
A woman is considered fertile following menarche and until becoming post-menopausal 
unless permanently sterile (see below). 
If fertility is unclear (e.g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot 
be confirmed before first dose of study intervention, additional evaluation should be 
considered. 
Women in the following categories are not considered WOCBP 
1. 
Premenarchal 
2. 
Premenopausal female with 1 of the following: 
• Documented hysterectomy 
• Documented bilateral salpingectomy 
• Documented bilateral oophorectomy 
For individuals with permanent infertility due to an alternate medical cause other than the 
above, (e.g., mullerian agenesis, androgen insensitivity), investigator discretion should be 
applied to determining study entry. 
Note: Documentation can come from the site personnel’s: review of the participant’s medical 
records, medical examination, or medical history interview. 
 
1. 
Postmenopausal female 
• A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal 
range may be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormonal replacement therapy (HRT). However, in the absence of 12 
months of amenorrhea, confirmation with more than one FSH measurement [insert 
threshold if required (>40 IU/L or mIU/mL) or remove to allow for flexibility with 
different local thresholds for defining postmenopausal state] is required.  
• Females on HRT and whose menopausal status is in doubt will be required to use one 
of the non-estrogen hormonal highly effective contraception methods if they wish to 
continue their HRT during the study. Otherwise, they must discontinue HRT to allow 
confirmation of postmenopausal status before study enrollment. 
• The investigator will collect pregnancy information on any female participant who 
becomes pregnant while participating in this study. Information will be recorded on 
the appropriate form and submitted to the sponsor within 24 hours of learning of a 
participant's pregnancy.  


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 50 of 54 
 
• The participant will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow-up information on the participant and the neonate, after 
obtaining the signed informed consent from both parents, unless local law or specific 
circumstances of the respective case allow otherwise, and the information will be 
forwarded to the sponsor. Generally, follow-up will not be required for longer than 6 
to 8 weeks beyond the estimated delivery date. Any termination of pregnancy will be 
reported, regardless of fetal status (presence or absence of anomalies) or indication for 
the procedure. 
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy will be reported as an AE or SAE. 
A spontaneous abortion is always considered to be an SAE and will be reported as 
such. Any post-study pregnancy related SAE considered reasonably related to the 
study intervention by the investigator will be reported to the sponsor as described in 
Section 8.3.5. While the investigator is not obligated to actively seek this information 
in former study participants, he or she may learn of an SAE through spontaneous 
reporting.  
• Any female participant who becomes pregnant while participating in the study will 
discontinue study intervention or be withdrawn from the study. 
 
 
  
 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 51 of 54 
 
10.5 
Appendix 5: Participant Assessments 
 
Categorical Pain Intensity Scale (predose) 
 
Finish the statement: “My pain at this time is” by checking the appropriate box. 
 
⁭ No Pain (0) 
⁭ Mild Pain (1) 
⁭ Moderate Pain (2) 
⁭ Severe Pain (3) 
 
 
Numerical Rating Scale (predose and post-dose) 
 
Circle a number to indicate level of pain (from 0 to 10) below to indicate the severity of the 
pain you are experiencing at this time. 
 
No  
pain 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Worst 
possible 
pain 
 
 
 
Categorical  Pain Relief Rating Scale (post-dose) 
 
Finish the statement: “ My relief from my starting pain is”” by checking the appropriate 
box. 
 
 
☐ No Relief (0) 
☐  A Little Relief (1) 
☐ Some Relief (2) 
☐ A Lot of Relief (3) 
☐ Complete Relief (4) 
 
 
 
 
 
 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 52 of 54 
 
Half Way Pain Relief (post-dose) 
 
Finish the statement: “Is your starting pain at least ½ gone?” by checking the appropriate 
box. 
 
 
☐ No (0) 
 
☐ Yes (1) 
 
 
 
Global Assessment of Pain (post-dose) 
 
Finish the statement: “ What is your overall rating of the study medication you received?” 
by checking the appropriate box. 
 
 
☐ Poor (0) 
☐ Fair (1) 
☐ Good (2) 
☐ Very Good (3) 
☐ Excellent (4) 
 
 
 
 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 53 of 54 
 
10.6 
Appendix 6: Abbreviations 
 
 
AE 
Adverse Event 
ANCOVA 
Analysis of Covariance 
CDER 
Center for Drug Evaluation and Research 
CDISC 
Clinical Data Interchange Standards Consortium 
CI 
Confidence Interval 
COX 
Cyclooxygenase 
CRO 
Clinical Research Organization 
CSR 
Clinical Study Report 
(e)CRF 
(electronic) Case Report Form  
EOT 
End of Trial 
FDA 
Food and Drug Administration 
GCP 
Good Clinical Practice 
GMP 
Good Manufacturing Practice 
IB 
Investigator Brochure 
ICF 
Informed Consent Form 
ICH 
International Conference on Harmonization 
IMP 
Investigational Medicinal Product 
IRB/IEC 
Institutional Review Board/Independent Ethics Committee 
ITT 
Intent-to-Treat 
MedDRA 
Medical Dictionary for Regulatory Activities 
NPO 
nil per os 
NRS 
Numerical Rating Scale 
NSAID 
Nonsteroidal Anti-inflammatory Drug 
OTC 
Over-the-Counter 
PID 
Pain Intensity Differences 
PP 
Per Protocol 
QA 
Quality Assurance 
RNR 
Randomization Number 
SAE 
Serious Adverse Event 
SAP 
Statistical Analysis Plan 
SAS 
Statistical Analysis Software 
SNR 
Screening Number 
SSRI 
Selective Serotonin Uptake Inhibitors 
SoA 
Schedule of Activities 
SOC 
System Organ Class 
SPID 
Summed Pain Intensity Difference 
SUSAR 
Serious Unexpected Adverse Reaction 
TEAE 
Treatment-Emergent Adverse Event 
TOTPAR 
Total Pain Relief 


CONFIDENTIAL 
Clinical Study Protocol 
BAY 117031 / 20536 
Version 1.0 / 19 Nov 2019                     Page 54 of 54 
 
11. 
References 
• Brune K. Persistence of NSAIDs at effect sites and rapid disappearance from side-
effect compartments contributes to tolerability. Curr Med Res Opinion. 
2007;23(12):2985-2995. 
• Cooper SA, Beaver WT. A model to evaluate mild analgesics in oral surgery 
outpatients. Clin Pharmacol Ther 1976;20:241-50. 
• Cooper SA and Desjardins PJ. The value of the dental impaction pain model in drug 
development.  Methods Mol Biol,  Szallasi A, Ed.   Humana Press  617: 175-190, 
2010. 
• Cooper SA, Desjardins PJ, Turk DC, et al. Research design considerations for single-
dose analgesic clinical trials in acute pain: IMMPACT recommendations.  Pain 
2016;157:288-301. 
• Desjardins PJ, Black PM, Balm TK, et al. Onset of analgesia: Further validation of a 
new stopwatch methodology. Clin Pharmacol,: 1996;59:130. Abstract. 
• Desjardins PJ, Black P, Papageorge M, Norwood T, Shen DD, Norris L, Ardia A. 
Ibuprofen arginate provides effective relief from postoperative dental pain with more 
rapid onset of action than ibuprofen. Eur J Clin Pharmacol 2002;58(6):387-394. 
• Kiersch TA, Halladay SC, and Hormel PC. A Single-Dose, Double-Blind Comparison 
of Naproxen Sodium, Acetaminophen, and Placebo in Postoperative Dental Pain. Clin 
Ther 1994;16(3):394-404. 
• Kleinert R, Lange C, Steup A, Black P, Goldberg J, Desjardins P.  Single dose 
analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, 
double-blind, placebo-controlled study. Anesth Analg. 2008;107:2048-55. 
• 
 Prescribing Information, 08/2019. 
• Singla NK, Desjardins PJ, Chang PD.  A comparison of the clinical and experimental 
characteristics of four acute surgical pain models: dental extraction, bunionectomy, 
joint replacement, and soft tissue surgery. Pain. 2014;155:441-56. 
• Practice Guidelines for Preoperative Fasting and the Use of Pharmacologic Agents to 
Reduce the Risk of Pulmonary Aspiration: Application to Healthy Patients Undergoing 
Elective Procedures: An Updated Report by the American Society of Anesthesiologists 
Task Force on Preoperative Fasting and the Use of Pharmacologic Agents to Reduce 
the Risk of Pulmonary Aspiration. Anesthesiology 2017;126(3):376-393. 
• Sharma CV, Mehta V. Paracetamol: mechanisms and updates. Continuing Education 
in Anaesthesia, Critical Care and Pain. 2014,14: 153-8. 
• Hydrocodone/Acetaminophen U.S. Department of Health and Human Services Food 
and Drug Administration Center for Drug Evaluation and Research (CDER).  
Guidance for Industry Analgesic Indications: Developing Drug and Biological 
Products. February 2014. 
https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guid
ances/ucm384691.pdf Accessed July 16, 2017. 
CCI

SAP_001.pdf: 
 
Document Type: 
Statistical Analysis Plan 
Official Title: 
A Randomized, Double-Blind, Placebo-Controlled Trial to Compare 
the Analgesic Efficacy and Safety of Naproxen Sodium Tablets and 
Hydrocodone/Acetaminophen Tablets in Postsurgical Dental Pain 
NCT Number: 
NCT04307940 
Document Date: 
21 JAN 2021 
 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
 
 
 
 
 
STATISTICAL ANALYSIS PLAN 
 
TITLE PAGE 
 
 
 
 
A Randomized, Double-Blind, Placebo-Controlled Trial to Compare the Analgesic 
Efficacy and Safety of Naproxen Sodium Tablets and Hydrocodone/Acetaminophen 
Tablets in Postsurgical Dental Pain 
 
  
 
 
 
Final Version 1.0: JAN 21, 2021 
 
 
 
 
Confidentiality Statement 
The information contained in this document is privileged and confidential.  Do not copy, 
circulate, or otherwise distribute without written authorization from  
Bayer HealthCare LLC, Consumer Health 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
 
 
 
TABLE OF CONTENTS 
PAGE 
 
TITLE PAGE ........................................................................................................................... 1 
TABLE OF CONTENTS ......................................................................................................... 2 
DECLARATION ..................................................................................................................... 4 
REVISION HISTORY............................................................................................................. 5 
LIST OF ABBREVIATIONS .................................................................................................. 6 
1 
INTRODUCTION ................................................................................................... 8 
2 
STUDY DETAILS .................................................................................................. 8 
2.1 
Study Objectives...................................................................................................... 8 
2.2 
Study Design ........................................................................................................... 9 
2.3 
Determination of Sample Size ............................................................................... 12 
2.4 
Randomization....................................................................................................... 12 
2.5 
Blinding ................................................................................................................. 12 
3 
DATA ANALYSIS CONSIDERATION .............................................................. 13 
3.1 
Handling of Missing Data ..................................................................................... 13 
3.1.1 
Handling of Missing Data for Efficacy Assessments ............................................ 13 
3.1.2 
Handling of Missing Data for Safety Evaluations................................................. 14 
4 
DEFINITIONS & DERIVATIONS ...................................................................... 16 
4.1.1 
Endpoint Derivations ............................................................................................. 16 
5 
PRIMARY AND SECONDARY ENDPOINTS .................................................. 21 
5.1 
Primary Endpoint .................................................................................................. 21 
5.2 
Secondary Endpoints ............................................................................................. 21 
5.3 
Other Pre-Specified Endpoints .............................................................................. 21 
6 
ANALYSIS POPULATION AND TREATMENT GROUPS ............................. 22 
6.1 
Analysis Population ............................................................................................... 22 
6.2 
Treatment Groups .................................................................................................. 22 
7 
ANALYSIS METHODS AND REPORTING DESCRIPTION ........................... 23 
7.1 
Analysis Methods .................................................................................................. 23 
7.1.1 
Disposition............................................................................................................. 23 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 3 of 44 
 
 
 
7.1.2 
Demographic and Baseline Characteristics ........................................................... 23 
7.1.3 
Medical or Medication or Surgical History ........................................................... 23 
7.1.4 
Prior and Concomitant Medications ...................................................................... 24 
7.1.5 
Protocol Deviation ................................................................................................. 24 
7.1.6 
Study Drug Exposure and Treatment Compliance ................................................ 24 
7.1.7 
Efficacy Analysis .................................................................................................. 25 
7.1.7.1 
Primary Endpoint .................................................................................................. 25 
7.1.7.2 
Secondary Endpoints ............................................................................................. 25 
7.1.7.3 
Other pre-specified Endpoints ............................................................................... 27 
7.1.8 
Summary of Efficacy Endpoint Analysis Strategy................................................ 30 
7.1.9 
Safety Analysis ...................................................................................................... 34 
7.1.10 
PK/PD Analysis ..................................................................................................... 36 
7.1.11 
Pooled Analyses .................................................................................................... 36 
7.1.12 
Subgroup Analyses ................................................................................................ 37 
7.1.13 
Interim Analysis .................................................................................................... 37 
7.1.14 
Changes to Analyses Specified in Protocol ........................................................... 37 
8 
REFERENCE ........................................................................................................ 37 
9 
APPENDIX ........................................................................................................... 38 
 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
 Private and Confidential 
  Study No 20536 
    Date: JAN 21, 2021 
CONFIDENTIAL 
 Page 4 of 44 
DECLARATION 
I, the undersigned, declare that I have prepared the statistical analysis plan along with TFL mock-ups and that 
to the best of my knowledge this document is internally consistent with protocol and scientifically rational. 
Prepared by: 
        ________________           
               Sign & Date (MMM DD, YYYY) 
I, the undersigned declare that I have reviewed the statistical analysis plan along with TFL mock-ups and that 
to the best of my knowledge the document is internally consistent with protocol and scientifically rational. 
Reviewed by: 
             ________________ 
               Sign & Date (MMM DD, YYYY) 
SPONSOR AUTHORIZATION: I, the undersigned, declare that I have reviewed the statistical analysis plan 
along with TLF mock-ups and that to the best of my knowledge the document accurately reflects the protocol 
objectives. 
Authorized by: 
             ________________ 
Name:  
           Sign & Date (MMM DD, YYYY)
PPD
Name: 
Designation/ Role: PPD
PPD
PPD
Name: 
Designation/ Role: 
PPD
PPD


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 5 of 44 
 
 
 
REVISION HISTORY 
Version 
Date 
Author 
Reasons 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 6 of 44 
 
 
 
LIST OF ABBREVIATIONS 
Abbreviation or special term 
Explanation 
AE 
Adverse Event 
ANCOVA 
Analysis of Covariance 
ATC 
Anatomical Therapeutic Chemical 
BMI 
Body Mass Index 
CI 
Confidence Interval 
CM 
Concomitant Medication 
CRF 
Case Report Form 
ICH 
International Conference on Harmonization 
ITT 
Intent-To-Treat 
LS 
Least Square 
MedDRA 
Medical Dictionary for Regulatory Activities 
MME 
Morphine Milligram Equivalent 
NRS 
Numeric Rating Scale 
OTC 
Over-The-Counter 
PAR 
Pain Relief 
PI 
Pain Intensity 
PID 
Pain Intensity Difference 
PP 
Per Protocol 
PT 
Preferred Term 
SAE 
Serious Adverse Event 
SAP 
Statistical Analysis Plan 
SAS 
Statistical Analysis Software 
SD 
Standard Deviation 
SOC 
System Organ Class 
SPID 
Summed Pain Intensity Difference 
TEAE 
Treatment-Emergent Adverse Event 
TFLs 
Tables, Figures, and Listings 
TOTPAR 
Total Pain Relief 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 7 of 44 
 
 
 
Abbreviation or special term 
Explanation 
WHODRUG 
World Health Organization Drug Dictionary 
 
 
 
 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 8 of 44 
 
 
 
1 
INTRODUCTION 
This is single center, randomized, double-Blind, parallel, placebo-controlled study, stratified by 
baseline pain, in participants experiencing moderate to severe postoperative dental pain to compare 
the analgesic efficacy and safety of Naproxen Sodium tablets and Hydrocodone/Acetaminophen 
tablets in postsurgical dental pain. 
Both naproxen sodium and Hydrocodone/Acetaminophen are widely used analgesics. However, the 
relative efficacy of over-the-counter dosing with naproxen sodium has not been compared to 
hydrocodone/acetaminophen for relief of acute pain. This assessment is important and timely as 
options for reducing the use of opioid analgesics in postoperative pain control are highly desired. 
Understanding the relative efficacy and safety of alternative analgesics can provide clinicians with 
important information when they select appropriate analgesics for their patients. 
This Statistical Analysis Plan (SAP) describes the statistical methods and data handling procedures to 
be followed during the final reporting and analyses of data collected for the study Protocol 20536.  
This SAP should be read in conjunction with the study protocol and Case Report Form (CRF). This 
version of the plan has been developed using the protocol version 1.0 dated NOV 19, 2019 and CRF 
version 4.0 dated APR 21, 2020. 
The table of contents and templates for the Tables, Figures and Listings (TFLs) will be produced in a 
separate document. Any deviations from this SAP will be described and justified in the Clinical Study 
Report (CSR). 
The preparation of this SAP has been based on International Conference on Harmonization (ICH) E9. 
2 
STUDY DETAILS 
2.1 
Study Objectives 
 
The primary objective of the study is to compare the analgesic efficacy of a single oral dose of 
naproxen sodium 440 mg (2 x 220 mg tablets) relative to hydrocodone/acetaminophen 10/650 mg (2 
x 5/325 mg tablets) and placebo in participants experiencing moderate to severe post-impaction 
surgery dental pain. 
 
The secondary objectives of the study are: 
1. To compare the amount of pain relief produced by a single oral dose of naproxen sodium 440 
mg (2 x 220 mg tablets) relative to hydrocodone/acetaminophen 10/650 mg (2 x 5/325 mg 
tablets) and placebo in participants experiencing moderate to severe post-impaction surgery 
dental pain. 
 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 9 of 44 
 
 
 
2. To compare the time to first use of rescue medication of a single oral dose of naproxen sodium 
440 mg (2 x 220 mg tablets) relative to hydrocodone/acetaminophen 10/650 mg (2 x 5/325 mg 
tablets) and placebo in participants experiencing moderate to severe post-impaction surgery 
dental pain 
 
3. To compare the duration of pain intensity at least half gone for each timepoint of a single oral 
dose of naproxen sodium 440 mg (2 x 220 mg tablets) relative to hydrocodone/acetaminophen 
10/650 mg (2 x 5/325 mg tablets) and placebo in participants experiencing moderate to severe 
post-impaction surgery dental pain  
Other pre-specified objectives of the study are: 
To compare the following parameters of a single oral dose of naproxen sodium 440 mg (2 x 220 mg 
tablets) relative to hydrocodone/acetaminophen 10/650 mg (2 x 5/325 mg tablets) and placebo in 
participants experiencing moderate to severe post-impaction surgery dental pain: 
1. Summed Pain Intensity Difference  
2. Total pain relief 
3. Pain Intensity Difference (PID) 
4. Proportion/percent of participants with Pain Half Gone 
5. Global assessment of the investigational product 
To compare the incidence of GI and Nervous system side effects produced by a single oral dose of 
naproxen sodium 440 mg (2 x 220 mg tablets) relative to hydrocodone/acetaminophen 10/650 mg (2 
x 5/325 mg tablets) and placebo. 
2.2 
Study Design 
This is a single center, randomized, double-blind, parallel, placebo-controlled study, stratified by 
baseline pain, in participants experiencing moderate to severe postoperative dental pain. The study 
will consist of a Prescreening telephone call, a Screening Visit, a one-day Treatment Period and a 
Post-Operative visit. Eligible participants who have undergone surgical extraction of three or four 
third molars, 2 of which must be mandibular partial or full bony impacted third molars will be 
randomized into one of three treatment groups and kept in-house and evaluated for efficacy and safety 
at the study center through completion of all trial procedures. For an overview on the study design 
study procedures see the figure 1 below. 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 10 of 44 
 
 
 
 
Screening Phase 
Eligible participants will be screened and selected up to 28 days prior to oral surgery and dosing with 
investigational product. 
Treatment Phase 
Following selection, qualified participants will enter the Treatment Phase and be scheduled for their 
surgical teeth extractions. After completion of the surgical teeth extractions, participants will remain 
at the study site for observation. Participants with appropriate pain severity for randomization will 
then be stratified by baseline pain intensity and randomized into one of three (3) treatment groups. 
Participants will rate their pain severity and pain relief over the next 12 hours. Onset of analgesia will 
be measured using a two-stopwatch approach. The first stopwatch will be used to capture the time 
when any pain relief is first perceived and in certain cases the second stopwatch will be used to capture 
the time when pain relief becomes meaningful to the participant. After completion of all trial 
procedures, participants will be discharged from the study site. 
Follow-Up Phase 
Participants will be evaluated at a post-operative visit/call approximately 2-5 days after discharge for 
follow up for any adverse events or medications not known at the time of treatment. 
The duration of each participant’s participation will be approximately 37 days.  
The Schedule of Assessments for the study is presented below in the Table 1. 
 
 
 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 11 of 44 
 
 
 
Table 1: Schedule of Assessment 
 
 
 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 12 of 44 
 
 
 
2.3 
Determination of Sample Size  
Assuming that the treatment difference of 12.3 and common standard deviation of 15.5 with respect 
to SPID0-12, a total of approximately 200 subjects (80 subjects per active treatment arm and 40 in the 
placebo using a 2:2:1 ratio) are required to achieve at least 90% of power with the type I error of 0.05, 
a total of approximately 210 subjects will be randomized into the study if a drop-out rate of 5% is 
assumed. 
2.4 
Randomization 
On Day 1, participants will be assigned a unique number (randomization number) in ascending 
numerical order at the study site. The randomization number encodes the participant’s assignment to 
one of the three (3) arms of the study, according to the randomization schedule generated prior to the 
study by the Sponsor. Each participant will be dispensed blinded study intervention, labelled with 
his/her unique randomization number, throughout the study. 
2.5 
Blinding 
Participants enrolled in the trial, investigators and their staff involved in protocol procedures or who 
are involved in data collection, data entry and data analysis will be blinded to the identity of the 
treatments until the database is locked. The study monitor will conduct product accountability after 
database lock. To preserve blinding, participants will be blindfolded during administration of study 
medication. Study drug will be dispensed by an unblinded study team member based on the 
randomization schedule. That team member may have no other role in the study conduct and may not 
reveal the study drug’s identity to any members of the blinded study team. 
 
 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 13 of 44 
 
 
 
3 
DATA ANALYSIS CONSIDERATION 
The statistical analyses will be performed by Quartesian Clinical Research, using SAS Version 9.3 or 
higher. All Tables, Figures and Listings (TFLs) will be produced in landscape format. In general, all 
data will be listed by the subject, treatment and visit/time point where as appropriate. 
Data will be summarized by treatment group and visit/time. The total number of subjects in the 
treatment group (N) under the stated population will be displayed in the header of summary tables. 
Data will be summarized using descriptive statistics for continuous variables. Unless otherwise stated, 
descriptive statistics will include total number of subjects (n), mean, standard deviation (SD), 
minimum, median, and maximum. In case of n<2, where n indicates the number of evaluable subjects 
at the particular time point, only n, mean, minimum and maximum will be displayed. The statistic 
“Missing” will also be evaluated by enumerating the number of missing entries/subjects, if any at that 
visit, and presented as a summary statistic only for the resulting time points. 
In summary tables of categorical variables, counts and percentages will be used. The count [n] 
indicates the actual number of subjects with a particular value of a variable or event, which should 
always be less than or equal to the total number of subjects in the respective treatment group [N]. 
Percentage will be obtained by: % = (n/N) *100. Unless otherwise stated. 
Proportion will be obtained by: (n/N). 
For ordinal-scaled variables, a combination of the above may be employed as appropriate: frequency 
and percentage of observations within a category and means and standard deviations of the scores of 
the categories. For categorical and ordinal variables, percentages will be calculated based on non-
missing data. 
Decimal Precision Convention: The minimum and maximum statistics will be presented to the same 
number of decimal places as the original data. The mean and median will be presented to one more 
decimal place than the original data, whereas the standard deviation will be presented to two more 
decimal places than the original data. Also, the lease square mean, standard error and its confidence 
interval, least square mean differences will be presented to two more decimal places than the original 
data. All percentages will be expressed to one decimal place. P-value will be presented three decimal 
places or P-value closer to zero will be presented as <0.001 and P-value closer to one will be presented 
as >0.999. 
All dates will be displayed in DDMMMYYYY format. 
3.1 
Handling of Missing Data 
3.1.1 Handling of Missing Data for Efficacy Assessments 
Use of Rescue Medication: In all analyses, for participants who take rescue medication, all pain 
intensity scores after intake of rescue medication will be imputed by the worse of the baseline or the 
score assessed immediately before taking rescue medication. All pain relief after intake of rescue 
medication will be imputed by “no relief” (0). All pain at least half gone after intake of rescue 
medication will be imputed by “NO”. 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 14 of 44 
 
 
 
Missing data for efficacy parameter:  
If subjects have missing pain data (i.e. pain intensity or pain relief scores) within the 12 hours period 
for the collection of pain rating data, but nonetheless complete the 12-hour period, then any missing 
timepoints will be replaced by a time-weighted average of the previous and the next available values 
(i.e. a linear interpolation for missing values) of the pain data (pain intensity/ pain relief 
score).Intermittent missing data will only be imputed using linear interpolation method. 
Interpolation Formula, 
𝑦𝑦= 𝑦𝑦2 −𝑦𝑦1
𝑥𝑥2 −𝑥𝑥1
(𝑥𝑥−𝑥𝑥1) + 𝑦𝑦1 
 
Where, y=missing pain data to be imputed, x= respective timepoint of y 
𝑦𝑦1 𝑎𝑎𝑎𝑎𝑎𝑎 𝑦𝑦2= pre and post available pain score of the missing pain data 
𝑥𝑥1 𝑎𝑎𝑎𝑎𝑎𝑎 𝑥𝑥2= respective timepoints of 𝑦𝑦1 𝑎𝑎𝑎𝑎𝑎𝑎 𝑦𝑦2 
If subjects do not complete the pain intensity assessments for the full 12 hours, then in the primary 
analysis, the SPID0-12 and TOTPAR0-12 will be calculated up to the last available timepoint, with no 
imputation for later timepoints.  
In a sensitivity analysis, subjects who drop out of the study early because of a related AE or lack of 
efficacy will have later missing timepoints imputed using a worst-observation-carried-forward 
(WOCF) method, in which their worst observation at baseline or any time thereafter is imputed. For 
subjects dropping out early for any other reason, a last-observation-carried-forward (LOCF) 
imputation will be used. 
No imputation will be done for missing data on stopwatch assessments of perceptible and meaningful 
pain relief. Instead, if data are missing for those assessments, data will be censored as described in 
Section 4.1.1. 
If the subject’s global evaluation of the study medication is missing, a value of 0 (poor) will be 
imputed. 
For all post-dose timepoints missing values with pain at least pain half gone will be imputed by “NO”. 
3.1.2 
Handling of Missing Data for Safety Evaluations 
To handle missing or partial AE and concomitant medication dates, the following rules will be 
applied. 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 15 of 44 
 
 
 
For Partial Start Dates: 
 
1. If the year is unknown, then do not impute the date but assign a missing value. 
2. If the month is unknown, then: 
i. 
If the year matches the year of the dose date, then impute the month and day of the dose date. 
ii. 
Otherwise, assign “January.” 
3. If the day is unknown, then: 
i. 
If the month and year match the month and year of the dose date, then impute the day of the 
dose date. 
ii. 
Otherwise, assign “01.” 
 
For Partial End Dates: 
 
1. If the year is unknown, then do not impute the date but assign a missing value. 
2. If the month is unknown, then assign “December.” 
3. If the day is unknown, then assign the last day of the month. 
After implementing the rules above, to determine whether AEs (or medications) with missing start or 
stop dates are pre-treatment or on/after treatment, the following strategy will be used: 
1. If the start date and stop date are both missing, then the most conservative approach is taken 
and the AE (or medication) is considered to be treatment emergent (or concomitant medication). 
 
2. If the start date is missing but the stop date is not missing and is on or after the day of study 
dose administration, then the most conservative approach is taken and the AE (or medication) 
is considered to be treatment emergent (or concomitant medication). 
 
3. If the start date is missing but the stop date is not missing and is before the day of study dose 
and after the date of signed informed consent, then the AE (or medication) is considered to be 
before treatment (or prior medication). 
 
4. If the start date is not missing but the stop date is missing, then the most conservative approach 
is taken, and medication is considered to be concomitant while the AE is defined by start date. 
 
5. If the Adverse Event Relationship flag is missing, the relationship for adverse event will be 
imputed and will be considered as “Yes”. If the Adverse Event Severity flag is missing, the 
severity will be imputed and will be considered as severe. 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 16 of 44 
 
 
 
4 
DEFINITIONS & DERIVATIONS 
Baseline: For all parameters, baseline will be defined as the last non-missing value before the first 
treatment administration. 
Change from Baseline: The change from baseline values will be calculated as post-baseline value 
minus the baseline value. 
     Change from Baseline=Post baseline value - Baseline value 
Treatment Emergent Adverse Event (TEAE): A treatment-emergent adverse event (TEAE) is any 
AEs that begin or worsen after the first dose of the study drug administration in the Treatment Phase. 
4.1.1 
Endpoint Derivations 
Pain Intensity 
Subjects will assess their current pain intensity using an 11-point (0: No Pain to 10: Worst possible 
pain) Numerical Rating Scale (NRS). Each subject will be instructed to mark the number indicating 
his or her current pain intensity. Below is pain scale format. 
No 
Pain 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Worst 
possible 
pain 
 
The subject is to record pain intensity (NRS) at baseline (i.e. pre-dose). Thereafter, the subject is to 
record NRS pain intensity assessment at the following time points during the 12 hours period after 
baseline: 
• 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose, and immediately before each use of 
rescue analgesia. 
i 
Nominal Ti (hours) 
0 
0 
1 
0.5 
2 
1 
3 
1.5 
4 
2 
5 
3 
6 
4 
7 
5 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 17 of 44 
 
 
 
8 
6 
9 
7 
10 
8 
11 
9 
12 
10 
13 
11 
14 
12 
 
Pain Intensity Difference 
Pain intensity difference (PID) is to be calculated by subtracting the pain intensity at the post-dose 
time point from the pain intensity at baseline. 
𝑃𝑃𝑃𝑃𝑃𝑃𝑖𝑖= 𝑃𝑃𝑃𝑃0 −𝑃𝑃𝑃𝑃𝑖𝑖; for all i > 0. 
Where, PI0 pain intensity at baseline, PIi is the PI score at post-dose time point i 
Summed Pain Intensity Difference (SPID) 
The summed pain intensity difference (SPID) is to be calculated by multiplying the PID score at each 
post dose time point by the duration (in hours) since the preceding time point and then summing the 
values over the relevant time period. 
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 0−12 = ෍൫𝑇𝑇𝑖𝑖−𝑇𝑇(𝑖𝑖−1)൯∗𝑃𝑃𝑃𝑃𝑃𝑃𝑖𝑖
14
𝑖𝑖=1
 
𝑆𝑆𝑃𝑃𝑃𝑃𝑃𝑃 9−12 = ෍൫𝑇𝑇𝑖𝑖−𝑇𝑇(𝑖𝑖−1)൯∗𝑃𝑃𝑃𝑃𝑃𝑃𝑖𝑖
14
𝑖𝑖=11
 
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 8−12 = ෍൫𝑇𝑇𝑖𝑖−𝑇𝑇(𝑖𝑖−1)൯∗𝑃𝑃𝑃𝑃𝑃𝑃𝑖𝑖
14
𝑖𝑖=10
 
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 6−12 = ෍൫𝑇𝑇𝑖𝑖−𝑇𝑇(𝑖𝑖−1)൯∗𝑃𝑃𝑃𝑃𝑃𝑃𝑖𝑖
14
𝑖𝑖=8
 
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 0−8 = ෍൫𝑇𝑇𝑖𝑖−𝑇𝑇(𝑖𝑖−1)൯∗𝑃𝑃𝑃𝑃𝑃𝑃𝑖𝑖
10
𝑖𝑖=1
 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 18 of 44 
 
 
 
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 0−6 = ෍൫𝑇𝑇𝑖𝑖−𝑇𝑇(𝑖𝑖−1)൯∗𝑃𝑃𝑃𝑃𝑃𝑃𝑖𝑖
8
𝑖𝑖=1
 
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 0−4 = ෍൫𝑇𝑇𝑖𝑖−𝑇𝑇(𝑖𝑖−1)൯∗𝑃𝑃𝑃𝑃𝑃𝑃𝑖𝑖
6
𝑖𝑖=1
 
Where T0=0, Ti is actual post-dose time, PIDi is the PID score at post-dose time Ti for all i > 0. 
The durations between two time points will be calculated using the actual post-dose times of the pain 
score measurement. If the actual time is missing, then the nominal planned time will be used. 
Pain Relief 
Subjects will assess their current pain relief using a 5-point (0: No relief, 1: A little relief, 2: Some 
Relief, 3: A Lot of Relief, 4: Complete relief) categorical scale. Each subject will be instructed to mark 
the number indicating his or her current pain relief. 
The subject is to record pain relief (5-point categorical rating scale) at given time points during the 
12-hour period and immediately before first use of rescue medication. 
Total Pain Relief (TOTPAR) 
Total pain relief (TOTPAR) is calculated by multiplying the pain relief score at each time point by the 
duration (in hours) since the preceding time point and then summing these over the relevant period. 
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 0−12 = ෍൫𝑇𝑇𝑖𝑖−𝑇𝑇(𝑖𝑖−1)൯∗𝑃𝑃𝑃𝑃𝑃𝑃𝑖𝑖
14
𝑖𝑖=1
 
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 9−12 = ෍൫𝑇𝑇𝑖𝑖−𝑇𝑇(𝑖𝑖−1)൯∗𝑃𝑃𝑃𝑃𝑃𝑃𝑖𝑖
14
𝑖𝑖=11
 
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 8−12 = ෍൫𝑇𝑇𝑖𝑖−𝑇𝑇(𝑖𝑖−1)൯∗𝑃𝑃𝑃𝑃𝑃𝑃𝑖𝑖
14
𝑖𝑖=10
 
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 6−12 = ෍൫𝑇𝑇𝑖𝑖−𝑇𝑇(𝑖𝑖−1)൯∗𝑃𝑃𝑃𝑃𝑃𝑃𝑖𝑖
14
𝑖𝑖=8
 
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 0−8 = ෍൫𝑇𝑇𝑖𝑖−𝑇𝑇(𝑖𝑖−1)൯∗𝑃𝑃𝑃𝑃𝑃𝑃𝑖𝑖
10
𝑖𝑖=1
 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 19 of 44 
 
 
 
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 0−6 = ෍൫𝑇𝑇𝑖𝑖−𝑇𝑇(𝑖𝑖−1)൯∗𝑃𝑃𝑃𝑃𝑃𝑃𝑖𝑖
8
𝑖𝑖=1
 
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 0−4 = ෍൫𝑇𝑇𝑖𝑖−𝑇𝑇(𝑖𝑖−1)൯∗𝑃𝑃𝑃𝑃𝑃𝑃𝑖𝑖
6
𝑖𝑖=1
 
Where T0=0, Ti is actual post-dose time, PARi is the Pain Relief score at post-dose time Ti for all i>0 
Peak Pain Relief  
Peak pain relief is the highest observed value of pain relief experienced during post-dose assessments 
of the study.  
Peak Pain Intensity Difference (PID) 
Peak pain intensity difference is the highest observed value of pain intensity difference calculated by 
formula given above in this section.  
 
Duration of Pain at least Half Gone 
Duration of pain at least half gone will be calculated by the time between the timepoints when pain at 
least half gone was firstly reported and the subsequent time point when pain at least half gone was 
firstly reversed or the time of last assessment if pain at least half gone was retained for all subsequent 
time points.  
If the pain at least half gone is secondly reported after the firstly reversed pain half gone and secondly 
reversed, then duration of pain at least half gone will be the sum of these two-time intervals. The 
duration will be set to 0 when no pain at least half gone was ever reported throughout the assessment 
period. 
 
Time to first Perceptible Relief 
Time to first perceptible relief is the time when the subject experiences any perceptible pain relief after 
administration of study drug and stops the first stopwatch. If it is not stopped, time will be censored at 
the time of last pain relief score assessment or at the first use of rescue medication, whichever comes 
first. 
Time to meaningful relief 
Time to meaningful relief is the time when the subject experiences relief that is meaningful after the 
administration of study drug and stops the second stopwatch. If it is not stopped, time will be censored 
at the time of last pain relief score assessment or at the first use of rescue medication, whichever comes 
first. 
 
 
 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 20 of 44 
 
 
 
Time to first perceptible relief confirmed by meaningful relief 
Time to first perceptible relief confirmed by meaningful relief is defined as the time to perceptible 
pain relief (the first stopwatch time) for those subjects who had confirmed meaningful pain relief 
immediately after first stopwatch and it will be time to meaningful pain relief (the second stopwatch 
time) for those subjects who did not confirm the meaningful relief before second stopwatch. If 
stopwatch is not stopped, time will be censored at the time of last pain relief score assessment or at 
the first use of rescue medication, whichever comes first. 
Time to the First Use of Rescue Medication 
Time to first use of rescue medication for pain is defined as the time from first study drug 
administration to the first use of rescue medication. If rescue medication for pain is not taken, the time 
will be censored at the time of the last pain intensity score assessment. 
Amount of Rescue Medication Used  
To quantify opioids use, the amount of rescue medications (opioids) will be converted to a standard 
unit, which is Morphine Milligram Equivalent (MME) using below formula, 
 
MME/Day = Strength per Unit * (Number of units / Day supply) * MME conversion factor 
Cumulative proportion of subjects taking rescue medication 
The cumulative proportion of subjects taking rescue medication will be calculated as the cumulative 
number of subjects who taken rescue medication by a given timepoint divided by the number of 
subjects treated in respective treatment group. 
Cumulative percent of subjects with Pain at least half gone 
Cumulative percentage of subjects with pain at least half gone will be calculated as the cumulative 
number of subjects with pain at least half gone at given timepoint divided by the number of subjects 
treated in respective treatment group.  
 
Subjects with ‘at least a 2-point PID’  
Subjects with ‘at least a 2-point PID’ will be calculated as  𝑃𝑃𝑃𝑃𝑃𝑃𝑖𝑖= 𝑃𝑃𝑃𝑃0 −𝑃𝑃𝑃𝑃𝑖𝑖 ; for all i > 0.  
Where, PI0 pain intensity at baseline, PIi is the PI score at post-dose time point i 
Subjects with observed PID score greater than or equal to 2 at any post dose timepoints will be 
considered as ‘at least a 2-point PID’. 
Subject’s Global Assessment of Investigational Product 
At hour 12 or immediately prior to the first dose of rescue medication (if prior to hour 12), study 
participants will be asked to provide a Global Assessment of investigational product after completion 
of the other assessments. The subject will be instructed to score his or her global evaluation of the 
study treatment on a 5-point categorical scale where 0 = poor, 1 = fair, 2 = good, 3 = very good, and 
4 = excellent. 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 21 of 44 
 
 
 
5 
PRIMARY AND SECONDARY ENDPOINTS  
5.1 
Primary Endpoint 
 Sum of Pain Intensity Difference over 12 hours (SPID 0-12)  
5.2 
Secondary Endpoints 
 Total Pain Relief over 12 hours (TOTPAR 0-12) 
 Total Pain Relief over 6 hours (TOTPAR 0-6) 
 Sum of Pain Intensity Difference over 6 hours (SPID 0-6) 
 Amount of Rescue Medication Used 
 Time to first use of rescue medication over 12 hours 
 Duration of Pain at Least Half Gone over 12 hours 
 Duration of Pain at Least Half Gone over first 6 hours 
5.3 
Other Pre-Specified Endpoints 
 The SPID 0-4, 0-8, 6-12, 8-12, and 9-12 
 TOTPAR 0-4, 0-8, 6-12, 8-12, and 9-12 
 Pain Intensity Difference (PID) and Pain Relief scores at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 
11, and 12 hours post-dose 
 Time to first perceptible relief measured by a stopwatch, time to meaningful relief measured 
by a stopwatch, and time to first perceptible relief confirmed by meaningful relief defined as 
the time to perceptible pain relief (the first stopwatch time) for those subjects who had 
meaningful pain relief (the second stopwatch time) 
 The cumulative proportion of subjects taking rescue medication over the 12-hour period. 
 Peak PID and peak pain relief 
 Percent of participants with Pain Half Gone at least once over 12 hours 
 Percent of participants with Pain Half Gone at each time point over 12 hours 
 Proportion of participants with pain at least one-half gone at each time point 
 Cumulative percent of subjects with Pain at least half gone will be plotted over time 
 Cumulative percent of subjects with ‘at least a 2-point PID’ will be plotted over time 
 Global Assessment of the investigational product 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 22 of 44 
 
 
 
 Percent of subjects reporting GI and Nervous system AEs prior to use of rescue medication 
6 
ANALYSIS POPULATION AND TREATMENT GROUPS  
6.1 
Analysis Population  
Randomized Population 
All subject who received a randomization number, regardless of receiving study medication. 
Safety Population 
All subjects who are randomized and take at least one dose of investigational product. Safety measures 
will be analysed for all subjects in safety population. 
Intent-To-Treat (ITT) Population 
All subjects in the Safety Population who provide at least one pain (pain intensity/ pain relief score) 
assessment after the first dose of the investigational product. ITT population will be used as secondary 
to conduct the sensitivity analysis for the selected parameters. 
Per protocol (PP) Population 
PP population will include all subjects in ITT who do not have any major protocol violations and 
complete the 12-hour assessments. PP population will be used as the primary analysis for the 
efficacy parameters. 
Major protocol deviations will be identified prior to database lock and may include but are not limited 
to significant violations of inclusion/exclusion criteria, noncompliance of the trial treatment taken, 
conditions such as vomiting and diarrhea or use of prohibited medications, and not following clinical 
trial protocol procedures. Any subject who rescues or vomits at or prior to 60 minutes after ingesting 
study medication will be excluded from the PP population. 
6.2 
Treatment Groups 
The below table includes the treatment labeling for all Tables, Listings and Figures (wherever as 
appropriate): 
Treatment 
        Treatment Label for TLF 
Naproxen sodium 440 mg  
        Naproxen 
Hydrocodone / Acetaminophen 10/650 mg 
        Hydrocodone 
Placebo 
        Placebo 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 23 of 44 
 
 
 
7 
ANALYSIS METHODS AND REPORTING DESCRIPTION  
7.1 
Analysis Methods 
7.1.1 
Disposition 
Subject disposition will be summarized using frequency count and percentage by treatment group and 
overall, for the randomized subjects: 
• 
The number of subjects Randomized  
• 
The number of subjects in safety population 
• 
The number of subjects in ITT population 
• 
The number of subjects in Per-Protocol population 
• 
The number of subjects who completed the study 
• 
The number of subjects who discontinued early, as well as the reason for 
discontinuation 
Subjects’ disposition status will be listed by treatment group and will include subject number, , study 
completion status, Date of completion or discontinuation, and for those who discontinued early, 
specific reason for discontinuation (if reason of discontinuation is “Lost to follow-up” then “Date of 
last contact:” will be listed. 
7.1.2 
Demographic and Baseline Characteristics 
Demographic and baseline characteristics (including age, gender, race, ethnicity, childbearing 
potential, method of contraception, weight, height, BMI) will be summarized by treatment group and 
for the overall using descriptive statistics (n, mean, SD, median, minimum, and maximum) for Safety 
and ITT population. Demographic and baseline data will also be listed for safety population.  
Dental X-ray examination, Surgical Trauma Rating and social history will be listed separately for 
safety population. 
7.1.3 
Medical or Medication or Surgical History 
A complete medical history, including a complete review of all current and past diseases will be done 
on screening visit. Medical history term will be coded using the Medical Dictionary for Regulatory 
Activities (MedDRA) version 23.0. and summarized by treatment group and overall, by frequency 
count and percentage of subjects in each system organ class (SOC), preferred term (PT) using Safety 
Population.  
Subjects will be counted only once at the preferred term (PT), only once at the system organ class 
(SOC), and only once at subject level for the counting of total number of subjects with a medical 
history term. Counts will be presented in descending frequency unless otherwise specified. 
Listings of medical history events for subjects in the Safety Population will be provided. 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 24 of 44 
 
 
 
7.1.4 
Prior and Concomitant Medications 
Any medication other than study drug, either prescription drug or over the counter (OTC) will be 
treated as concomitant medication. 
Prior Medications 
For a subject in the Safety Population, prior medications will include any medication taken prior to 
subject’s first dose of Study Medication. 
Concomitant Medications 
Concomitant medications are defined as prescribed medications and over the counter (OTC) 
preparations, including herbal preparations and vitamins, other than Study medication taken during 
the treatment phase. 
Prior and concomitant medication will be categorized by preferred Term and ATC level X class per 
World Health Organization Drug Dictionary (WHODRUG; Version 2019SEP01) will be summarized 
by treatment group and overall, for the Safety Population. The frequency count and percentage of 
subjects using each medication will be displayed. Subjects who taken the same medication (in terms 
of PT) more than once will be counted only once for that medication. 
Subjects taking multiple prior/ concomitant medication will be counted only once in summary table. 
If the subject is taking medication prior to study drug administration and continues the same drug after 
study drug administration, then such subjects will be summarized in both prior and concomitant 
medication summary tables. 
All prior and concomitant medications will be presented in a listing for the Safety Population.  
7.1.5 
Protocol Deviation 
Protocol deviations will be identified and classified as minor or major before un-blinding. Protocol 
deviations occurring during the clinical trial will be summarized descriptively by treatment group and 
overall. A listing and summary of protocol deviations will be presented using the Safety Population.   
7.1.6 
Study Drug Exposure and Treatment Compliance 
A summary table of study drug administration will be provided. Table will be presented using counts 
and percentages of Number of units administered by treatment groups. 
A listing of study drug exposure (administration/dispensation) will be provided. 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 25 of 44 
 
 
 
7.1.7 
Efficacy Analysis 
7.1.7.1 
Primary Endpoint 
The primary efficacy endpoint is the sum of pain intensity Difference over 12 hours (SPID0-12). The 
treatment comparisons will be made in the following sequential order for SPID0-12 (each at 0.05 level 
of significance) in order to protect overall type 1 error at 0.05: 
• Naproxen sodium 440 mg versus Placebo 
• Naproxen sodium 440 mg versus hydrocodone/acetaminophen 10/650 mg 
• Hydrocodone/acetaminophen 10/650 mg versus Placebo 
Once a comparison is statistically non-significant, the subsequent comparisons will be technically 
ineligible to be declared significant. However, all comparisons will be presented to provide a complete 
picture. 
The primary efficacy endpoint is the summed pain intensity difference over 0 to 12 hours after Time 
0 (SPID0-12). The formula for SPID0-12 calculation is presented in Section 4.1.1. The primary efficacy 
endpoint will be analysed using an analysis of covariance (ANCOVA) model, which will include 
SPID0-12 as dependent variable, treatment as main effect and baseline pain intensity as the covariate. 
The least square (LS) mean, standard error (SE) and 95% confidence interval (CI) for each treatment 
group will be estimated. In addition, the mean (LS mean) difference between each treatment and 
placebo, SE, p-value and the associated 95% CI will also be computed. Descriptive statistics (including 
n, mean, SD, median, minimum, and maximum) will also be presented by treatment group. PP 
population (without imputation) will be used as the primary analysis for this primary endpoint. ITT 
population (without imputation and single imputation) will be used as secondary to conduct the 
sensitivity analysis. 
 
In the primary analysis, endpoint will be imputed as described in Section 3.1.1 if any pain assessments 
are missing and if subjects take rescue medication. 
7.1.7.2 Secondary Endpoints 
Analysis of the secondary endpoints will be summarized according to the variable type. The details 
are presented in the following sections.  
SPID over 0 to 6 hours (SPID 0-6) 
SPID 0-6 will be calculated using the formula specified in Section 4.1.1. The same method that is used 
for the analysis of the primary endpoint will be used to assess the difference between the treatment 
groups in each metric. This endpoint will be analysed using PP population (without imputation) as 
primary analysis. ITT population (without imputation and single imputation) will be used as secondary 
to conduct the sensitivity analysis. 
 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 26 of 44 
 
 
 
In the secondary analysis, endpoint will be imputed as described in Section 3.1.1 if any pain 
assessments are missing and if subjects take rescue medication. 
Total pain relief (TOTPAR) over 0 to 12 hours (TOTPAR 0-12), over 0 to 6 hours (TOTPAR 0-
6) 
TOTPAR over 0-12, 0-6 hours will be calculated using the formula specified in Section 4.1.1. The 
differences in TOTPAR between the treatment groups and placebo will compared using an analysis of 
covariance (ANCOVA) model, which will include TOTPAR as the dependent variable, treatment as 
main effect and baseline pain intensity as the covariate. The least square (LS) mean, standard error 
(SE) and 95% confidence interval (CI) for each treatment group will be estimated. In addition, the 
mean (LS mean) difference between each treatment and placebo, SE, p-value and the associated 95% 
CI will also be computed. Descriptive statistics (including n, mean, SD, median, minimum, and 
maximum) will also be presented by treatment group. PP population (without imputation) will be used 
as the primary analysis for TOTPAR0-12, TOTPAR0-6 endpoints. ITT population (without imputation 
and single imputation) will be used as secondary to conduct the sensitivity analysis of TOTPAR0-12, 
and TOTPAR0-6.  
In the secondary analysis, endpoints will be imputed as described in Section 3.1.1 if any pain 
assessments are missing and if subjects take rescue medication. 
Amount of Rescue Medication Used 
The amount of analgesic rescue medication (Morphine Milligram Equivalent) used through 12 hours 
will be summarized. Medications will be converted to tramadol equivalents using the conversion table. 
(MME) using the conversion table which is provided in Appendix 1. If any rescue medication is not 
received in (mg/ mcg) units which is given in Appendix 1, then site/sponsor will provide the data in 
relevant units. Results (amount of rescue medication use) will be compared using an ANOVA model 
which include amount of rescue medication used as dependent variable and treatment as independent 
variable if the assumptions of normality and heterogeneity of variance meets. If these assumptions are 
violated, a non-parametric Wilcoxon Rank Sum test will be used. Descriptive statistics (including n, 
mean, SD, median, minimum, and maximum) will also be presented by treatment group. This endpoint 
will be analysed using PP population as primary analysis and ITT population as secondary to conduct 
the sensitivity analysis. 
Time to First Use of Rescue Medication 
Time to first use of rescue medication will be estimated and plotted using Kaplan-Meier method. 
Censoring will be applied as described in Section 4.1.1. Median time will be compared between the 
treatment groups and placebo using a log-rank test stratified by baseline pain intensity. The summary 
statistics (25th percentile, Median, 75th percentile and it 95% CI) and K-M estimates of overall time to 
first use of rescue medication with 95% CI will be presented by treatment groups. This endpoint will 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 27 of 44 
 
 
 
be analysed using PP population as primary analysis and ITT population as secondary to conduct the 
sensitivity analysis.  
Duration of Pain at Least Half Gone over 12 hours and 6 hours 
Duration of pain at least half gone calculation is presented in Section 4.1.1. The duration of pain at 
least half gone will be analysed using an analysis of covariance (ANCOVA) model, which will include 
duration of pain at least half gone as dependent variable, treatment as main effect and baseline pain 
intensity as the covariate. The least square (LS) mean, standard error (SE) and 95% confidence interval 
(CI) for each treatment group will be estimated. In addition, the mean (LS mean) difference between 
each treatment and placebo, SE, p-value and the associated 95% CI will also be computed. This 
endpoint will be analysed using PP population as primary analysis and ITT population as secondary 
to conduct the sensitivity analysis.  
7.1.7.3 Other pre-specified Endpoints 
Analysis of the other pre-specified endpoints will be summarized according to the variable type. The 
details are presented in the following sections. The analysis of all below endpoints will be performed 
on PP population with no imputation. 
SPID 0-4, 0-8, 6-12, 8-12 and 9-12 
SPID 0-4, SPID 0-8, SPID  6-12, SPID 8-12, SPID 9-12 will be calculated using formulas specified 
in the Section 4.1.1. The same method that is used for the analysis of the primary endpoint will be 
used to assess the difference between the treatment groups in each metric.  
TOTPAR 0-4, 0-8, 6-12, 8-12 and 9-12 
TOTPAR 0-4, TOTPAR 0-8, TOTPAR 6-12, TOTPAR 8-12, TOTPAR 9-12 will be calculated using 
formulas specified in the Section 4.1.1. The same method that is used in secondary endpoint, Total 
pain relief (TOTPAR) over 0 to 12 hours will be used to assess the difference between the treatment 
groups in each metric.  
Pain Intensity Difference (PID) and Pain Relief scores at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 
and 12 hours post-dose 
The PID at each scheduled time point will be calculated using the formula specified in Section 4.1.1. 
Descriptive statistics (including mean, SD, median, minimum and maximum) will also be presented 
by treatment groups. Pain Relief score categories will be presented in the form of counts and 
percentage by treatment groups and overall. Also, the pain relief score at each scheduled time point 
will be summarised using descriptive statistics (including mean, SD, median, minimum and 
maximum) by treatment groups.  


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 28 of 44 
 
 
 
A graphical illustration of the time effect curve (Time versus Mean PID/ Mean pain relief score) will 
be presented. 
Time to first perceptible relief, time to meaningful relief, time to first perceptible relief 
confirmed by meaningful relief  
Time to first perceptible pain relief, time to meaningful relief and time to first perceptible relief 
confirmed by meaningful relief will be estimated and plotted using Kaplan-Meier methods. The 
definitions and censoring rules are defined in Section 4.1.1. Median time will be compared between 
the treatment groups and placebo using a log-rank test stratified by baseline pain intensity. The 
summary statistics (25th percentile, Median, 75th percentile and it 95% CI) and overall K-M estimates 
with 95% CI will be presented by treatment groups. 
Cumulative proportion of subjects taking rescue medication over the 12 hours period 
Cumulative proportion of subjects taking rescue medication will be calculated as the cumulative 
number of subjects who takes rescue medication at given timepoint and percentage will be calculated 
by cumulative number of subjects who takes rescue medication at given timepoint divided by the 
number of subjects treated in respective treatment group.   
The cumulative proportion of subjects taking rescue medication over 12 hours period will be presented 
using counts and proportion with timepoints (0.5, ≤1, ≤1.5, ≤2, ≤3, ≤4, ≤5, ≤6, ≤7, ≤8, ≤9, ≤10, ≤11, 
≤12) by treatment groups and curves over time will be plotted by treatment group. 
Frequency tables will be tabulated for the number of times that the subject took rescue medication 
over the 12 hours period. 
Subject will be counted only once in cumulative addition. 
Peak PID and peak pain relief 
The peak PID and peak pain relief score for each subject will be identified using the description in 
Section 4.1.1. The data for this endpoint will be summarised by treatment group using counts and 
percentage. 
Percent of participants with Pain Half Gone at least once over 12 hours 
Participants with pain at least half gone will be identified using the method mentioned in Section 4.1.1. 
The percent of participants with pain half gone at least once by 12 hours will be summarised by 
treatment group using count and percentage and will be analysed using chi square test to compare the 
proportion among the treatment groups. 
 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 29 of 44 
 
 
 
Percent of participants with Pain Half Gone at each time point over 12 hours 
Participants with pain half gone at each time point will be identified using the method mentioned in 
Section 4.1.1. The percent of participants with pain half gone at each time point over 12 hours will be 
summarised by treatment group using count and percentage and will be analysed using chi square test 
to compare the proportion among the treatment groups at each time point. The proportion of subjects 
with pain at least half gone at each timepoint will be plotted over time by treatment group. 
Cumulative percent of subjects with Pain at least half gone 
Subjects with pain at least half gone will be identified using the method mentioned in Section 4.1.1. 
Cumulative percent of subjects with pain at least half gone will be calculated as the cumulative number 
of subjects with pain at least half gone at given timepoint divided by the number of subjects treated in 
respective treatment group. The cumulative percent of subjects with pain at least half gone will be 
presented using counts and percent with timepoints (0.5, ≤1, ≤1.5, ≤2, ≤3, ≤4, ≤5, ≤6, ≤7, ≤8, ≤9, ≤10, 
≤11, ≤12) by treatment groups and curves over time will be plotted by treatment group. Subject will 
be counted only once in cumulative addition. 
Cumulative percent of subjects with ‘at least a 2-point PID’  
Subjects with 2-point PID will be identified using the method mentioned in Section 4.1.1. The 2-point 
PID is the subject PID which is greater than or equal to 2 at post baseline records. Cumulative percent 
of subjects with at least a 2-point PID will be calculated as the cumulative number of subjects with 2-
point PID at given timepoint divided by the number of subjects treated in respective treatment group. 
The cumulative percent of subjects with ‘at least a 2-point PID’ will be presented using counts and 
percent with timepoints (0.5,≤1, ≤1.5, ≤2, ≤3, ≤4, ≤5, ≤6, ≤7, ≤8, ≤9, ≤10, ≤11, ≤12) by treatment 
groups and curves over time will be plotted by treatment group. Subject will be counted only once in 
cumulative addition. 
Global Assessment of the investigational product 
Global assessment of the investigational product ratings poor (0), fair (1), good (2), very good (3), 
excellent (4), will be tabulated using counts and percentage by treatment group and will be analysed 
using Cochran-Mantel-Haenszel (CMH) test with modified ridit score controlling baseline pain 
intensity as strata. Since this is ordinal scale rating, mean score difference will be used for treatment 
comparison. 
 
 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 30 of 44 
 
 
 
7.1.8 
Summary of Efficacy Endpoint Analysis Strategy 
Endpoint 
Statistical 
Method/Test 
Analysis 
Population 
Missing Data 
Imputation 
Approach 
Parameters/ 
Variables 
In the Analysis 
Analysis 
Time Point 
 
Primary Efficacy Endpoint 
Sum of Pain 
Intensity 
Difference 
over 12 hours 
(SPID 0-12) 
ANCOVA, 
Descriptive 
statistics 
PP 
No 
imputation 
SPID derived from 
pain intensity score 
12 hours 
Sum of Pain 
Intensity 
Difference 
over 12 hours 
(SPID 0-12) 
ANCOVA, 
Descriptive 
statistics 
ITT 
No 
imputation 
and Single 
imputation  
SPID derived from 
pain intensity score 
12 hours 
 
Secondary Efficacy Endpoint 
Total Pain 
Relief over 12 
hours 
(TOTPAR 0-
12) 
ANCOVA, 
Descriptive 
statistics 
PP 
No 
imputation 
TOTPAR derived 
from pain relief 
score 
12 hours 
Total Pain 
Relief over 12 
hours 
(TOTPAR 0-
12) 
ANCOVA, 
Descriptive 
statistics 
ITT 
No 
imputation 
and Single 
imputation 
TOTPAR derived 
from pain relief 
score 
12 hours 
Total Pain 
Relief over 6 
hours 
(TOTPAR 0-
6) 
ANCOVA, 
Descriptive 
statistics 
PP 
No 
imputation 
TOTPAR derived 
from pain relief 
score 
 
6 hours 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 31 of 44 
 
 
 
Total Pain 
Relief over 6 
hours 
(TOTPAR 0-
6) 
ANCOVA, 
Descriptive 
statistics 
ITT 
No 
imputation 
and Single 
imputation 
TOTPAR derived 
from pain relief 
score 
 
6 hours 
Sum of Pain 
Intensity 
Difference 
over 6 hours 
(SPID 0-6) 
ANCOVA, 
Descriptive 
statistics 
PP 
No 
imputation 
SPID derived from 
pain intensity score 
6 hours 
Sum of Pain 
Intensity 
Difference 
over 6 hours 
(SPID 0-6) 
ANCOVA, 
Descriptive 
statistics 
ITT 
No 
imputation 
and Single 
imputation 
SPID derived from 
pain intensity score 
6 hours 
Amount of 
Rescue 
Medication 
Used  
ANOVA, 
Descriptive 
statistics 
PP, ITT 
No 
imputation 
Number of units of 
rescue medication 
used 
12 hours 
Time to first 
use of rescue 
medication 
over 12 hours 
Kaplan 
Meier 
Estimation 
Summary 
and graph 
PP, ITT 
No 
imputation 
Rescue medication 
taken (Yes/No) 
12 hours 
Duration of 
Pain at Least 
Half Gone 
over 12 hours 
ANCOVA 
PP, ITT 
No 
imputation 
Pain at least half 
gone (Yes/No) 
12 hours 
Duration of 
Pain at Least 
Half Gone 
over first 6 
hours 
ANCOVA 
PP, ITT 
No 
imputation 
Pain at least half 
gone (Yes/No) 
6 hours 
 
Other Specified Endpoint 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 32 of 44 
 
 
 
The SPID 0-4, 
0-8,6-12, 8-12 
and 9-12 
ANCOVA, 
Descriptive 
statistics 
PP 
No 
imputation 
SPID derived from 
pain intensity score 
4,8, 6-12, 8-
12 and 9-12 
hours 
TOTPAR 0-4, 
0-8, 6-12,8-12 
and 9-12 
ANCOVA, 
Descriptive 
statistics 
PP 
No 
imputation  
TOTPAR derived 
from pain relief 
score 
4,8, 6-12, 8-
12 and 9-12 
hours 
Pain Intensity 
Difference 
(PID) and 
Pain Relief 
scores at 0.5, 
1, 1.5, 2, 3, 4, 
5, 6, 7, 8, 9, 
10, 11, and 12 
hours post-
dose 
Descriptive 
statistics, 
Graph 
PP 
No 
imputation 
PID derived from 
pain intensity score, 
Pain relief score 
0.5, 1, 1.5, 2, 
3, 4, 5, 6, 7, 8, 
9, 10, 11, and 
12 hours 
Time to first 
perceptible 
relief 
measured by a 
stopwatch  
Kaplan 
Meier 
Estimation 
Summary 
and graph 
PP 
No 
imputation 
 
Stopwatch 1 
12 hours 
Time to 
meaningful 
relief 
measured by a 
stopwatch 
Kaplan 
Meier 
Estimation 
Summary 
and graph 
PP 
No 
imputation 
Stopwatch 2 
At any 
timepoint 
after first 
perceptible 
pain relief 
measured in 
12 hours 
Time to first 
perceptible 
relief 
confirmed by 
meaningful 
relief 
Kaplan 
Meier 
Estimation 
Summary 
and graph 
PP 
No 
imputation 
Stopwatch 1/ 
Stopwatch 2 
At any time 
during 12 
hours 
The 
cumulative 
proportion of 
subjects 
Frequency 
table and 
graph 
PP 
No 
imputation 
Rescue medication 
taken (Yes/No) 
12 hours 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 33 of 44 
 
 
 
taking rescue 
medication 
over the 12-
hour period 
Peak PID  
Frequency 
table 
PP 
No 
imputation 
Pain intensity 
difference 
12 hours 
Peak pain 
relief 
Frequency 
table 
PP 
No 
imputation 
Pain relief 
12 hours 
Percent of 
participants 
with Pain Half 
Gone at least 
once over 12 
hours 
Frequency 
table, chi 
square test 
PP 
No 
imputation 
Pain Half Gone 
(Yes/No) 
12 hours 
Percent of 
participants 
with Pain Half 
Gone at each 
time point 
over 12 hours 
Frequency 
table, chi 
square test 
and graph 
PP 
No 
imputation 
Pain half gone 
12 hours 
Cumulative 
percent of 
subjects with 
Pain at least 
half gone will 
be plotted 
over time 
Frequency 
table and 
graph 
PP 
No 
imputation 
Pain at least half 
gone 
12 hours 
Cumulative 
percent of 
subjects with 
‘at least a 2-
point PID’ 
will be plotted 
over time 
Frequency 
table and 
graph 
PP 
No 
imputation 
Pain intensity 
12 hours 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 34 of 44 
 
 
 
 
7.1.9 
Safety Analysis 
All safety assessments, including AEs, treatment-emergent adverse events (TEAEs), clinical 
laboratory test results, vital signs and physical & oral examinations will be tabulated and listed by 
subject when applicable. The safety analysis will be performed for the Safety Population. 
 
The following variables will be evaluated to assess the safety of the investigational products: 
 
Adverse Events 
 
Adverse Events will be coded using (MedDRA version 23.0) AE coding system for purpose of 
summary tables. For each treatment group, adverse events will be summarized with frequency count 
and percentage by MedDRA SOC and PT. 
 
A subject experiencing the same AEs and TEAEs multiple times will be counted only once for that 
PT. Similarly, if a subject experience multiple AEs and TEAEs (preferred terms) within the same SOC 
then that subject will be counted only once for that SOC. When summarizing by severity, only event 
Global 
Assessment of 
the 
investigational 
product 
Frequency 
table, CMH 
test 
PP 
No 
imputation 
Overall rating 
12 hours 
Percent of 
subjects 
reporting GI 
and Nervous 
system AEs 
prior to use of 
rescue 
medication 
Frequency 
with 
percentage 
Safety 
population 
No 
imputation 
TEAE 
Start of study 
drug 
administration 
to EOT 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 35 of 44 
 
 
 
with highest severity will be counted. All AEs will be listed in chronological order of the events 
occurred. 
 
Treatment-emergent Adverse Events (TEAEs) 
A listing of TEAE and a listing of TEAE leading to leading to study discontinuation will be provided. 
Serious Adverse Events 
 
Adverse Events Leading to Study Drug Discontinuation 
 
 
 
An overview of AE summary will be presented by treatment group. It will include: 
Number of Subjects who had an AE 
Number of Subjects who had a Serious AEs 
Number of Subjects who had a TEAEs 
Number of Subjects who had a Serious TEAEs 
Number of Subjects who had a TEAEs with reasonable causal relationship to the study treatment 
Number of subjects with at least one treatment related serious TEAE 
Number of Subjects who had a TEAEs leading to study discontinuation 
Number of Subjects who had a TEAEs leading to death 
A summary of the frequency (number and percentage of subjects) of TEAEs by treatment group and 
overall will be presented by SOC, PT term. Similarly, summary results will be generated for TEAEs 
by treatment group and overall will be presented by SOC, PT and severity (mild, moderate, severe). 
A summary of the frequency (number and percentage of subjects) of TEAEs by treatment group will 
be presented by SOC, PT and “reasonable causal relationship” to the study treatment is recorded as 
“Yes” and “No”. Summary of TEAE by treatment groups Leading to Study Discontinuation will be 
presented by SOC, PT. 
SAEs will be summarized separately using frequency and percentage by SOC and PT for the Safety 
Population. All SAEs recorded on the CRF will be listed. 
All TEAEs leading to study drug discontinuation will be listed using the Safety Population. 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 36 of 44 
 
 
 
Deaths 
 
 
Clinical Laboratory Data 
 
Urine Drug Screen 
Urine Drug Screen Test will be summarized by result using count and percentage by treatment groups. 
Listing of Urine Drug Screen will be provided. 
Urine Pregnancy Test 
Urine Pregnancy Test will be summarized by result using count and percentage by treatment groups. 
Listing of Urine Pregnancy Test will be provided.  
Breath or Saliva Alcohol Test 
Breath or Saliva Alcohol Test will be summarized by the sample type and result using count and 
percentage by treatment groups.  Listing of Breath or Saliva Alcohol test will be provided. 
Electrocardiogram (ECG) 
No ECG will be performed for this study. 
Vital signs:  
Vital signs (systolic (mmHg) and diastolic (mmHg) blood pressure, heart rate (bpm), respiratory rate 
(breaths/minute) ) observed and change from baseline values will be summarized at each timepoint 
using the descriptive statistics (n, Mean, SD, Median, Minimum, Maximum) by treatment group using 
Safety population. Vital Sign data will be listed by individual time course for each parameter. 
 
Physical and Oral examination: 
All physical and oral examination findings will be listed. 
7.1.10 PK/PD Analysis 
No PK/PD analyses will be conducted in this trial. 
7.1.11 Pooled Analyses 
No pooled analyses will be conducted in this trial. 
All TEAEs leading to death will be listed using the Safety Population. 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 37 of 44 
 
 
 
7.1.12 Subgroup Analyses 
There is no planned subgroup analysis; however, subgroup and exploratory analysis may be conducted 
as Post-hoc analysis.  
7.1.13 Interim Analysis 
No interim analysis will be performed. 
7.1.14 Changes to Analyses Specified in Protocol 
1. As per the Agency’s (FDA) recommendation, the amount of rescue medication and its use 
over time are added to the SAP and will be reported in the CSR 
 
2. As per the sponsor requirement below exploratory endpoints are added to the SAP 
a. SPID 6-12 and SPID 9-12 
b. TOTPAR 6-12 and TOTPAR 9-12 
8 
REFERENCE 
1. E9 Statistical Principles for Clinical Trials, ICH Guideline, Federal Register, 1997 
2. Guideline for Industry: Structure and Content of Clinical Study Reports (ICH E3), July 1996 
3. Study Protocol 20536 version 1.0, 19 NOV 2019 
4. Ratitich, B. and O’Kelly, M. (2011), “Implementation of Pattern-Mixture Models Using 
Standard SAS/STAT Procedures” PharmaSUG. Available at 
https://www.pharmasug.org/proceedings/2011/SP/PharmaSUG-2011-SP04.pdf 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 38 of 44 
 
 
 
9 
APPENDIX 
Appendix 1: Opioid Oral Morphine Milligram Equivalent (MME) Conversion factors1,2  
 
1 The MME conversion factor is intended only for analytic purposes where prescription data is used to calculate 
daily MME. It is to be used in the formula: Strength per Unit X (Number of Units/ Days Supply) X MME 
conversion factor = MME/Day. This value does not constitute clinical guidance or recommendations for 
converting patients from one form of opioid analgesic to another. Please consult the manufacturer’s full 
prescribing information for such guidance. Use of this file for the purposes of any clinical decision-making 
warrants caution. 
2National Center for Injury Prevention and Control. CDC compilation of benzodiazepines, muscle relaxants, 
stimulants, zolpidem, and opioid analgesics with oral morphine milligram equivalent conversion factors, 2016 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 39 of 44 
 
 
 
version. 
Atlanta, 
GA: 
Centers 
for 
Disease 
Control 
and 
Prevention; 
2016. 
Available 
at 
https://www.cdc.gov/drugoverdose/media/. For more information, send an email to Mbohm@cdc.gov. 
3 Buprenorphine formulations with a FDA approved indication for Medication Assisted Treatment (MAT) are 
excluded from Medicare’s Overutilization Monitoring System’s opioid overutilization reporting. 
4The MME conversion factor for buprenorphine patches is based on the assumption that one milligram of 
parenteral buprenorphine is equivalent to 75 milligrams of oral morphine and that one patch delivers the 
dispensed micrograms per hour over a 24 hour day. Example: 5 ug/hr buprenorphine patch X 24 hrs = 120 
ug/day buprenorphine = 0.12 mg/day = 9 mg/day oral MME. In other words, the conversion factor not 
accounting for days of use would be 9/5 or 1.8. 
However, since the buprenorphine patch remains in place for 7 days, we have multiplied the conversion factor 
by 7 (1.8 X 7 = 12.6). In this example, MME/day for four 5 μg/hr buprenorphine patches dispensed for use over 
28 days would work out as follows: Example: 5 ug/hr buprenorphine patch X (4 patches/28 days) X 12.6 = 9 
MME/day. Please note that because this allowance has been made based on the typical dosage of one 
buprenorphine patch per 7 days, you should first change all Days Supply in your prescription data to follow this 
standard, i.e., Days Supply for buprenorphine patches= # of patches x 7. 
5 The MME conversion factor for fentanyl buccal tablets, sublingual tablets, and lozenges/troche is 0.13. This 
conversion factor should be multiplied by the number of micrograms in a given tablet or lozenge/troche. 
6 The MME conversion factor for fentanyl film and oral spray is 0.18. This reflects a 40% greater bioavailability 
for films compared to lozenges/tablets and 38% greater bioavailability for oral sprays compared to 
lozenges/tablets. 
7 The MME conversion factor for fentanyl nasal spray is 0.16, which reflects a 20% greater bioavailability for 
sprays compared to lozenges/tablets. 
8 The MME conversion factor for fentanyl patches is based on the assumption that one milligram of parenteral 
fentanyl is equivalent to 100 milligrams of oral morphine and that one patch delivers the dispensed micrograms 
per hour over a 24 hour day. Example: 25 ug/hr fentanyl patch X 24 hrs = 600 ug/day fentanyl = 60 mg/day 
oral morphine milligram equivalent. 
In other words, the conversion factor not accounting for days of use would be 60/25 or 2.4. 
However, since the fentanyl patch remains in place for 3 days, we have multiplied the conversion factor by 3 
(2.4 X 3 = 7.2). In this example, MME/day for ten 25 μg/hr fentanyl patches dispensed for use over 30 days 
would work out as follows: 
Example: 25 ug/hr fentanyl patch X (10 patches/30 days) X 7.2 = 60 MME/day. Please note that because this 
allowance has been made based on the typical dosage of one fentanyl patch per 3 days, you should first change 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 40 of 44 
 
 
 
all Days Supply in your prescription data to follow this standard, i.e., Days Supply for fentanyl patches= # of 
patches X 3. 
9 The CDC MME conversion factor to calculate morphine milligram equivalents is 3. CMS uses this conversion 
factor when analyzing Medicare population opioid use. CMS uses the graduated methadone MME conversion 
factors to calculate MME within the Overutilization Monitoring System (OMS) for identifying and reporting 
potential opioid overutilizers. https://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose-a.pdf. 
10 Tapentadol is a mu receptor agonist and norepinephrine reuptake inhibitor. Oral MMEs are based on degree 
of mu-receptor agonist activity, but it is unknown if this drug is associated with overdose in the same dose-
dependent manner as observed with medications that are solely mu receptor agonists 
We can get the above information at the below given link: 
https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Opioid-
Morphine-EQ-Conversion-Factors-Aug-2017.pdf 
 
 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 41 of 44 
 
 
 
Appendix 2: Tables, Figures and Listings  
Note: Since Mock TLFs is the running document; Hence some of the Tables Listings and figures presented in 
the below TOC may undergo changes may not reflect the same. 
Table No. 
Table Title 
Table 14.1.1.1 
Summary of Subject Disposition and Analysis Populations - Randomized Population 
Table 14.1.2.1 
Summary of Demographic and Baseline Characteristics - Safety Population 
Table 14.1.2.2 
Summary of Demographic and Baseline Characteristics - ITT Population 
Table 14.1.3.1 
Summary of Medical History/Surgical History - Safety Population 
Table 14.1.4.1 
Summary of Prior Medications - Safety Population 
Table 14.1.5.1 
Summary of Study Drug Administration – Safety Population 
Table 14.1.6.1 
Summary of Protocol Deviations - Safety Population 
Table 14.2.1.1 
Summary of Categorical Pain Intensity Score - PP Population 
Table 14.2.1.2.1 
Summary of Numerical Pain Intensity Score (PIS) - PP Population 
Table 14.2.1.2.2 
Summary of Pain Intensity Difference (PID) - PP Population 
Table 14.2.1.3 
Summary of Sum of Pain Intensity Difference (SPID 0-4, SPID 0-6, SPID 0-8, SPID 0-12, 
SPID6-12, SPID 8-12, SPID9-12) - PP Population 
Table 14.2.1.4 
Summary of Categorical Pain Relief Score - PP Population 
Table 14.2.1.5 
Summary of Pain Relief Score - PP Population 
Table 14.2.1.6 
Summary of Total Pain Relief (TOTPAR 0-4, TOTPAR 0-6, TOTPAR 0-8, TOTPAR 0-
12, TOTPAR6-12, TOTPAR 8-12, TOTPAR9-12) - PP Population 
Table 14.2.2.1.1 
Analysis of Sum of Pain Intensity Difference over 12 hours (SPID 0-12) - PP 
Population 
Table 14.2.2.1.2 
Analysis of Sum of Pain Intensity Difference over 12 hours (SPID 0-12) (No 
Imputation) - ITT Population – Sensitivity Analysis 
Table 14.2.2.1.3 
Analysis of Sum of Pain Intensity Difference over 12 hours (SPID 0-12) (Single 
Imputation) – ITT Population – Sensitivity Analysis 
Table 14.2.3.1 
Analysis of Total Pain Relief over 12 hours (TOTPAR 0-12) - PP Population 
Table 14.2.3.2 
Analysis of Total Pain Relief over 12 hours (TOTPAR 0-12) (No Imputation) - ITT 
Population - Sensitivity Analysis 
Table 14.2.3.3 
 Analysis of Total Pain Relief over 12 hours (TOTPAR 0-12) (Single Imputation) - 
ITT Population - Sensitivity Analysis 
Table 14.2.4.1 
Analysis of Total Pain Relief over 6 hours (TOTPAR 0-6) - PP Population 
Table 14.2.4.2 
Analysis of Total Pain Relief over 6 hours (TOTPAR 0-6) (No Imputation) - ITT 
Population – Sensitivity Analysis 
Table 14.2.4.3 
Analysis of Total Pain Relief over 6 hours (TOTPAR 0-6)  (Single Imputation) - ITT 
Population – Sensitivity Analysis 
Table 14.2.5.1 
Analysis of Sum of Pain Intensity Difference over 6 hours (SPID0-6) - PP Population 
Table 14.2.5.2 
Analysis of Sum of Pain Intensity Difference over 6 hours (SPID0-6) (No Imputation) 
- ITT Population - Sensitivity Analysis 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 42 of 44 
 
 
 
Table 14.2.5.3 
Analysis of Sum of Pain Intensity Difference over 6 hours (SPID0-6) (Single 
Imputation) - ITT Population - Sensitivity Analysis 
Table 14.2.6.1 
Analysis of Time to First Use of Rescue Medication - PP Population 
Table 14.2.6.2 
Analysis of Time to First Use of Rescue Medication - ITT Population - Sensitivity 
Analysis 
Table 14.2.6.3 
Analysis of amount of Rescue Medication Used - PP Population 
Table 14.2.6.4 
Analysis of amount of Rescue Medication Used - ITT Population - Sensitivity 
Analysis 
Table 14.2.7.1 
Analysis of Duration of Pain at Least Half Gone over 12 hours - PP Population 
Table 14.2.7.2 
Analysis of Duration of Pain at Least Half Gone over 12 hours - ITT Population – 
Sensitivity Analysis 
Table 14.2.7.3 
Analysis of Duration of Pain at Least Half Gone over 6 hours - PP Population 
Table 14.2.7.4 
Analysis of Duration of Pain at Least Half Gone over 6 hours - ITT Population – 
Sensitivity Analysis 
Table 14.2.8.1 
Analysis of SPID 0-4, SPID 0-8, SPID6-12, SPID 8-12 and SPID9-12 - PP Population 
Table 14.2.8.2 
Analysis of TOTPAR 0-4, TOTPAR 0-8, TOTPAR 6-12, TOTPAR 8-12 and TOTPAR 9-12 
- PP Population 
Table 14.2.9.1 
Analysis of Time to First Perceptible Relief - PP Population 
Table 14.2.9.2 
Analysis of Time to Meaningful Relief - PP Population 
Table 14.2.9.3 
Analysis of Time to First Perceptible Relief Confirmed by Meaningful Relief - PP 
Population 
Table 14.2.10.1 
Summary of cumulative proportion of subjects taking rescue medication over the 12-
hour period - PP Population 
Table 14.2.10.2 
Summary of number of times that the subject took rescue medication over the 12-
hour period - PP Population 
Table 14.2.11.1 
Summary of Peak Pain Intensity Difference (PID) - PP Population 
Table 14.2.11.2 
Summary of Peak Pain Relief - PP Population 
Table 14.2.12.1 
Summary of subjects with pain half gone at least once over 12 hours - PP Population 
Table 14.2.12.2 
Summary of subjects with pain at least half gone at each time point - PP Population 
Table 14.2.13.1 
Summary of cumulative percentage of subjects with pain at least half gone - PP 
Population 
Table 14.2.13.2 
Summary of cumulative percentage of subjects with at least a 2-point PID - PP 
Population 
Table 14.2.14.1 
Summary of Global Assessment of Pain Relief - PP Population 
Table 14.3.1.1 
Overall Summary of Adverse Events - Safety Population 
Table 14.3.1.2 
Summary of Adverse Events by System Organ Class and Preferred Term - Safety 
Population 
Table 14.3.1.3 
Summary of Serious Adverse Events by System Organ Class and Preferred Term - 
Safety Population 
Table 14.3.1.4 
Summary of Treatment-Emergent Adverse Events by System Organ Class and 
Preferred Term - Safety Population 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 43 of 44 
 
 
 
Table 14.3.1.5 
Summary of Treatment-Emergent Adverse Events by Severity, System Organ Class 
and Preferred Term - Safety Population 
Table 14.3.1.6 
Summary of Treatment-Emergent Adverse Events by Reasonable Causal 
Relationship to Study Drug, System Organ Class, Preferred Term - Safety 
Population 
Table 14.3.1.7 
Summary of Treatment-Emergent Adverse Events Leading to Study Discontinuation 
by System Organ Class and Preferred Term - Safety Population 
Table 14.3.5.1 
Summary of Vital Signs - Safety Population 
Table 14.3.6.1 
Summary of Breath or Saliva Alcohol Test - Safety Population 
Table 14.3.6.2 
Summary of Urine Drug Screen - Safety Population 
Table 14.3.6.3 
Summary of Urine Pregnancy Test - Safety Population 
Table 14.3.7.1 
Summary of Concomitant Medications - Safety Population 
Listing No. 
Listing Title 
Listing 16.1.7 
Listing of Randomization Scheme - Randomized Population 
Listing 16.2.1.1 
Listing of Subject Disposition - Randomized Population 
Listing 16.2.2 
Listing of Protocol Deviations - Safety Population 
Listing 16.2.4.1 
Listing of Subject Demographic and Baseline Characteristics - Safety Population 
Listing 16.2.4.2.1 
Listing of Medical/Medication/Surgical History - Safety Population 
Listing 16.2.4.2.2 
Listing of Social History - Safety Population 
Listing 16.2.4.2.3 
Listing of Dental X-ray/Oral Examination - Safety Population 
Listing 16.2.4.2.4 
Listing of Dental Surgery Information/Surgical Trauma Rating - Safety Population 
Listing 16.2.4.3.1 
Listing of Investigational Product Administration - Safety Population 
Listing 16.2.5.2 
Listing of Prior and Concomitant Medication - Safety Population 
Listing 16.2.5.3 
Listing of Rescue Medications - Safety Population 
Listing 16.2.6.1 
Listing of Subject Assessments - Safety Population 
Listing 16.2.6.2 
Listing of Stopwatch Assessment - Safety Population 
Listing 16.2.6.3 
Listing of Global Assessment of Pain Relief - Safety Population 
Listing 16.2.6.4 
Listing of Subject Assessments - Prior to Rescue Medication - Safety Population 
Listing 16.2.7.1 
Listing of Adverse Events - Safety Population 
Listing 16.2.7.2 
Listing of Treatment-Emergent Adverse Events - Safety Population 
Listing 16.2.7.3 
Listing of Treatment-Emergent Adverse Events Leading to Study Discontinuation - 
Safety Population 
Listing 16.2.7.4 
Listing of Serious Adverse Events - Safety Population 
Listing 16.2.7.5 
Listing of Deaths - Safety Population 
Listing 16.2.8.6.1 
Listing of Urine Pregnancy Test - Safety Population 
Listing 16.2.8.6.2 
Listing of Urine Drug Screen - Safety Population 
Listing 16.2.8.7 
Listing of Breath or Saliva Alcohol Test - Safety Population 
Listing 16.2.9.1 
Listing of Vital Signs - Safety Population 
Listing 16.2.9.2 
Listing of Physical Examination Abnormalities - Safety Population 


Bayer HealthCare LLC, Consumer Health 
Statistical Analysis Plan  
Final Version 1.0 
                                                           Private and Confidential 
                                               Study No 20536 
                                                     Date: JAN 21, 2021 
 
CONFIDENTIAL  
 
 
 
 
 
 
 
 
 
 Page 44 of 44 
 
 
 
Listing 16.2.9.3 
Listing of Discharge Details - Safety Population 
Listing 16.2.9.4 
Listing of Follow Up Call - Safety Population 
Figure No. 
Figure title 
Figure 14.2.6.1 
Kaplan-Meier Plot for Time to First Use of Rescue Medication - PP Population 
Figure 14.2.9.1 
Kaplan-Meier Plot for Time to First Perceptible Pain Relief - PP Population 
Figure 14.2.9.2 
Kaplan-Meier Plot for Time to Meaningful Pain Relief - PP Population 
Figure 14.2.9.3 
Kaplan-Meier Plot for Time to First Perceptible Pain Relief Confirmed by 
Meaningful Pain Relief - PP Population 
Figure 14.2.10.1 
Cumulative proportion of subjects taking rescue medication over the 12-hour period 
- PP Population 
Figure 14.2.13.1 
Cumulative percentage of subjects with Pain at Least Half Gone - PP Population 
Figure 14.2.13.2 
Cumulative percentage of subjects with at least a 2-point PID - PP Population 
Figure 14.2.1.2.2 
Pain Intensity Difference over 12 hours period - PP Population 
Figure 14.2.1.5 
Pain Relief Score over time – PP Population